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Abstract 
 
SYNTHESIS AND STUDY OF RIGIDIFIED NUCLEOSIDES ANALOGUES 
FOR PROBING THE IMPORTANCE OF THE DEOXYRIBOSE DNA 
BACKBONE 
 
By Han Yueh 
Under the direction of Professor Larry W. McLaughlin 
 
 Nucleic acids are the only biopolymers capable of encoding and 
transferring information, this property has placed them at the fundamental 
core of all living organisms, and made them a topic of intense research for 
over a century. The former studies in our laboratory on simplified nucleic acid 
backbones provided insight into how we might rationally alter nucleic acid 
structure into one that possesses properties not observed in natural DNA and 
RNA. Here the work began as an investigation into rigidified nucleic acid 
systems capable of functioning as DNA. 
The first rigidified nucleic acid system we designed, the cyclo-2’-
deoxynucleic acids, has a linkage between the C5’ of the ribose sugar and 
base to lock the χ angle into the similar angle as the native nucleoside. These 
rigidified bases show great impact towards the DNA structure, destabilizing 
XX 
 
double helix formation. This in fact can also be found in nature to inhibit the 
TATA binding protein associating with its target region. 
 The next generation of rigidified nucleosides has an extended 7-
membered ring instead of the 6-membered ring that was present in the first 
generation to push the base closer to the helical center. Both diastereomers of 
the ring-expanded-cyclo-2’-deoxyadenosine have been successfully 
synthesized and characterized and are ready to perform further studies. 
 The third system is the hydroxymethyl-cyclo-nucleosides. The 
modified nucleosides in this project not only have the same linkage as the 
cyclo-nucleosides in the first system to restrict the base rotation, but also 
have an extra carbon (C6’) to give the backbone more flexibility which might 
better stabilize a double helix than the first generation. 
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Chapter 1 
Introduction 
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1. Introduction 
1.1 Discovery of Nucleic Acids 
 In the late 1800’s, Miescher isolated a phosphorus and nitrogen 
containing substance that was commonly observed in various cell types, and 
started the research into this substance which he named “nuclein”.1
Research on nuclein has remained steady since then, and resulted in the 
discovery of ribose sugars linked through phosphodiester bonds forming long 
polymers (Figure 1.1). Klein and Thannhauser enzymatically cut these large 
and complex biopolymers down to the monomer level making it possible to 
determine real structural information. In 1951 Todd synthesized and 
confirmed the four deoxynucleoside monomers, and established the D-
configuration and β-glycosidic linkage successfully2,3. The key to success was 
the development of methods of phosphorylation; for example, the preparation 
of the 3’- and 5’- phosphates of deoxyadenosine (Figure 1.2)4. These results 
supported the linear structure through phosphodiester linkages and further 
explained the earlier crystallographic data produced by Astbury and 
Hammarsten which postulated a 3.34 Å repeating unit composed of flat 
nucleotides standing out perpendicularly to the rod shaped sugar-phosphate 
backbone. 
 Years later after Hammarsten and Astbury, Gullard postulated the 
presence of hydrogen bonding interactions between the purines (A, G) and 
pyrimidines (C, T). He suggested that these hydrogen bonds could involve  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The three major components, nucleobase, carbohydrate, and 
phosphodiester linkage  in a single strand of DNA. 
 
 
 
 
 
 
 
 
Figure 1.2. Todd’s synthesis of deoxyadenosine 3’- and 5’-phosphates. a) 
MeOH, NH3; b) (PhO)2P(O)OP(H)(O)OCH2Ph; c) N-chlorosuccinimide; d) 
H2/Pd on Carbon. Image taken from Blackburn4. 
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nucleotides either in adjacent chains or within a single chain. Chargaff then 
began to investigate the base composition of DNA from a variety of sources 
using the paper chromatography technique to separate the products of 
hydrolysis of DNA and employing an UV spectrophotometer to quantify their 
relative abundance.5 His research proved that the number of purines is 
always equal to the number of pyrimidines, and therefore supported 
Gullard’s postulation. 
 In 1953, while Watson and Crick were trying to construct a model of 
DNA structure whch was supported by previous research, they realized that 
the enols of T and G could actually tautomerize into the keto form.6 (Figure 
1.3) The most critical information came from the crystal data provided to 
them by Wilkins and Franklin. Franklin believed their crystal data showed a 
helix in which the nucleobases were sequestered from water on the inside of 
the helix with phosphate exposed on the exterior.  
 
 
 
 
 
 
 
Figure 1.3. Complemetary hydrogen-bonded base-pairs as proposed by 
Watson and Crick. The thymine and guanine are showing in the revised keto 
forms.7 
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Watson and Crick thereafter created a model with the following major 
features (Figure 1.4): 1. Two polynucleotide chains wind around the center 
axis to form a double helix. 2. Two DNA strands run in opposite directions 
(antiparallel), each one forms a right-handed helix. 3. The bases occupy the 
core of the helix, and the surface of the double helix contains two grooves 
with unequal width, major and minor grooves. 4. Each base forms hydrogen 
bonds with a base in the opposite strand resulting in a planar base pair. This 
is the phenomenon know as complementary base pairing, resulting in the 
specific association of the double helix.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Three-dimensional structure of DNA (left), complementary 
strands of DNA (right). Image taken from Voet.8 
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1.2 DNA Structure 
 A nucleotide is the phosphate ester of a nucleoside which is composed 
of a nitrogenous heterocyclic nucleobase, a five-carbon sugar 
(either ribose or 2-deoxyribose), and one phosphate group; it can also be 
called a nucleoside monophosphate. The phosphate group forms bonds with 
either the 2, 3, or 5-carbon of the sugar, with the C5 site most common. They 
are components of both ribonucleic acid (RNA) and deoxyribonucleic acid 
(DNA). 
 The nucleobases are either monocyclic pyrimidines or bicyclic purines. 
The major purines, adenine (A) and guanine (G), and are found in both DNA 
and RNA. The major pyrimidines are cytosine (C), thymine (T) found in DNA, 
cytosine and uracil (U) in RNA (Figure 1.5). In DNA, bases are connected at 
the anomeric position of 2-deoxy-D-ribose through a ring nitrogen forming the 
four nucleosides: 2’-deoxyadenosine (dA), 2’-deoxyguanosine (dG), 2’-
deoxycytidine (dC), and 2’-deoxythymidine (dT). 
 The nucleosides functionalized with phosphate esters are called 
nucleotides, and the simplest of them have a single hydroxyl group of the 
sugar esterified by a mono-phosphate; for example, adenosine 5’-phosphate is 
a 5’-ribonucleotides, also abbreviated as AMP (Figure 1.6). A pyrophosphoric 
ester on the 5’-hydroxyl group is adenosine 5’-biphosphate (ADP), and ATP 
for adenosine 5’-triphoosphate. Nucleotides containing two phosphate 
monoesters are called nucleoside bisphosphates. The nucleosides which have  
7 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. a) Structures of the five major nucleobases with the IUPAC 
numbering systems. b) Four major deoxyribonucleosides and the pentose 
carbon numbering system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Structure of common nucleotides. All present as the sodium salts 
as observed at neutral pH. 
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two neighboring hydroxyl groups connected to a single phosphate are called  
cyclic nucleotides, as cytosine 3’,5’-cyclic phosphate, cCMP. 
 The detailed conformational structure is defined by the torsion angles 
α, β, γ, δ, ε, and ζ along the phosphate backbone, θ for the sugar, and χ for the 
glycosidic bond (Figure 1.7). We can describe the shape of nucleotides more 
easily by other parameters, like the sugar pucker and the syn-anti 
conformation of the glycosidic bond. The sugar “puckering” describes the 
major displacement of C-2’ and C-3’ from the C1’-O4’-C4’ plane; the sugar 
moiety is flexible, but generally exits in two conformations: the 3’ endo for 
RNA and 2’ endo for DNA.  
  
 
 
 
 
 
 
 
 
Figure 1.7. Torsion angles for polynucleotide chains in the phosphate 
backbone and the structures of the C2’-endo and C3’-endo sugar puckers. 
Image taken from Blackburn4. 
 
 
 
 The plane of the bases is close to perpendicular to the sugars, it allows 
the bases to adopt two principle orientations (Figure 1.8). The anti 
β 
χ 
α 
θ0 
ζ 
ε 
γ 
δ θ1 
θ2 θ3 
θ4 
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conformation has the smaller H-6 of pyrimidine and the H-8 of purine on top 
of the sugar ring; the syn conformation has the larger atoms (O-2 on 
pyrimidine, N-3 on purine) in that position. While pyrimidines occupy a 
narrow angle of anti conformations; purines may be found in a wider range of 
anti conformations that can extend into high-anti conformations for some 8-
azapurine nucleosides.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. a) The range of glycosylic bonds in pyrimidine and purine nucleic 
acids for the Anti and Syn conformations. b) Examples of the anti 
conformation for deoxythimidine and the syn conformation for 
deoxyadenosine-5’-phosphate.  
 
 
 
 Crystal structures showed that DNA has a number of different forms. 
The three main types are the A-form, B-form, and the less common Z-form 
χ χ 
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(Figure 1.9). The biologically most common form of DNA is known as B-form 
DNA which was initially described by Watson and Crick. In the ideal B-form, 
the right-handed helix has 10 base pairs (bp) per turn, a helical twist of 36o 
per bp, and 34 Å rise per turn.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Structures of A-, B-, and Z-DNA forms. Image taken from Voet. 8 
 
 
 
Under dehydrating conditions, B-DNA can transform into A-DNA. A-
DNA has 11 bp per turn, a pitch of 28 Å, and a wider right-handed helix than 
in the B-form. One of the most noticeable features in A-DNA is that the 
planes of base pairs are tilted 20o with respect to the helix axis.  
DNA can be converted to the Z-form under certain conditions; such as  
alternating purine-pyrimidine sequence, especially poly(dGC)2, and high salt 
11 
 
condition. The salt stabilizes Z-DNA relative to the B-form by reducing the 
electrostatic repulsions between the closest approaching phosphate groups on 
opposite strands. Z-DNA has a left hand helix that results from an 
alternating syn-anti conformation of the nucleobases along the helix axis. 
 
 
1.3 Nucleic Acid Functions 
 DNA carries genetic information in all cells and in many viruses. Its 
primary function is the faithful storage and transmission of information from 
one generation to the next. Each strand of a DNA duplex acts as a template 
during replication. This process is not perfectly accurate, a low baseline level 
of mutation might occur. However these mutations have presumably allowed 
the evolution of many diverse forms of life. 
 According to the central dogma of molecular biology formulated by 
Crick in 1958, DNA directs its own replication and transcription to form an 
RNA of complementary sequence. The RNA is then translated into the 
corresponding amino acids to form proteins. In the ribosome, each set of three 
nucleotides in the mRNA (messenger RNA, a protein-coding gene) pairs with 
three complementary tRNA (transfer RNA, a small RNA molecule) 
nucleotides attached to the corresponding amino acid. The ribosome catalyzes 
the joining of amino acids, which are the monomeric units of proteins. 
12 
 
The discovery of the ribosome showed that RNA could also have 
chemical functionality. This discovery led to research on identifying 
numerous enzymatic RNAs, or so called ribozymes.9,10,11 
 
1.4 Rigidified Nucleic Acid 
 One class of nucleosides that has garnered much attention is the 
rigidified nucleic acids. These nucleosides contain a chemical modification 
that reduces the flexibility of the molecule. Our interest in this class of 
nucleosides is based on the design of a nucleic acid system which is capable of 
information storage and still has the same functionalities as native RNA and 
DNA like replication, transcription, and translation. We hypothesize that by 
controlling the rigidity and the structure of these nucleic acids further into 
the oligomers, we may be able to direct duplex formation. We believe that a 
suitable rigidified structure may be able to minimize the entropic cost during 
duplex formation and may even be capable of performing nonenzymatic 
template directed polymerization. 
 In the past few decades, there are a great number of structurally 
restrained nucleosides that have been synthesized. There are two major 
categories for these rigidified nucleosides; the first class of these contains a 
modified sugar moiety, the second class is constructed by creating a linkage 
between the sugar and the nucleobase to restrain the structure. 
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 In the first class, the modified nucleosides have a bicyclic or tricyclic 
ring system.12,13,14 Other than on the pentose sugar, the modification can be 
realized at a variety of locations through the formation of many unique 
bridges (Figure 1.10). These conformationally constrained nucleosides may 
have the ability to interact with natural DNA or RNA, and can potentially 
inhibit protein synthesis. Inhibition could be realized through a number of 
different mechanisms, depending on which section is chosen as the target, a 
mRNA or a non-spliced pre-mRNA. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.10. Conformationally restrained rigid nucleic acids, bicyclic and 
tricyclic (last two structures) molecules.15,16 The most well studied is the 
original LNA nucleoside. 
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The two most common inhibition mechanisms are through the arrest of 
translation by antisense oligonucleotides and/or the ubiquitous cellular 
enzymes. The advantage of this concept over traditional small molecule 
protein targeting in drug design is that ideally only minimal structural 
knowledge about the target RNA is required; i.e. one only needs to know the 
sequence. 
 The most well known and studied rigidified nucleosides of this class 
are the Locked Nucleic acids (LNA). In 1997, Imanishi from Japan initially 
synthesized the uridine and cytosine derivatives of LNAs. When analyzing 
the crystal structures, they found the extra linkage in LNA locks the 
structure into C3’-endo sugar puckering with an anti- nucleobase 
orientation.17 A year later, the Wengel group from Denmark published the 
synthesis of A, G, C, T, U, and 5-Me-C derivatives of LNAs, and incorporated 
these monomers into DNA strands or homo-polymers. Thermal studies 
indicated that these molecules not only formed stable duplexes with both 
DNA and RNA, but they also stabilized the structure by 7 – 8 ºC per modified 
base.11 The extra ring on the structure enhances the thermal stability of the 
duplex and improves the sequence specificity. The mechanisms behind this 
are the more favorable base stacking and lower entropic cost when the 
conformationally restrained nucleosides appear within an oligonucleotide 
duplex. 
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 Another type of rigidified nucleoside contains an extra linkage to 
connect the nucleobase with the carbohydrate. The structures of these 
modified nucleosides are usually more rigid than the molecules in the first 
class, like LNAs. The greater level of rigidity results from both the extra 
cyclization which helps to rigidify the sugar moiety as in LNA, and limited 
rotation of the nucleobase around the glycosidic bond. The base orientation in 
normal nucleosides resides mainly in the anti conformation, but the 
nucleobases are free to rotate around the glycosidic bond, since it is not fixed. 
 The research of rigidified nucleosides in our lab began with Dr. Allen 
Horhota. Dr. Horhota had been working on two series of rigidified nucleosides 
(Figure 1.11), the BTN (Bridged Threose Nucleic Acid) and aXNA (Anhydrous 
Xylose Nucleic Acid).18 BTN, which contains an extra methylene group to link 
the nucleobase with the C4’ of the threose sugar, is derived from the 
simplified nucleic acid TNA (Threose Nucleic Acid). The aXNA has an 
anhydrous bond between the base and 3’OH of the xylose sugar and shifts the 
connection of the sugar backbone from 3’OH-5’OH (in XNA) to 2’OH-5’OH (in 
aXNA). As mentioned above, the extra linkages in these two cyclized 
nucleosides not only rigidifies the entire structure, but locks the glycosidic 
bond in a fixed position.  
 These rigid nucleosides were designed to decrease the flexibility and 
restrict the conformational rotation which we hoped it would result in a 
better thermal stability of duplexes. Unfortunately, the result of the sequence 
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Figure 1.11. The structures of: a) Threose Nucleic Acid (TNA) and Bridged-
Threose Nucleic Acid (BTN); b) Xylose Nucleic Acid (XNA) and Anhydrous 
Xylose Nucleic Acid (aXNA). The rigidified nucleic acids, BTN and aXNA, 
have extra linkages to connect the base with sugar moiety and lock the χ 
torsion angle. 
 
studies showed that these molecules do not stabilize the helical structure, 
since there is no double helix formation when they were incorporated into a 
duplex. The reason for this could be due to the very rigid structure of these 
molecules, and also that the backbones are not in the natural orientation (3’ 
to 5’). In BTN, the backbone is 2’ to 3’; the backbone is 2’ to 5’ in aXNA. 
This thesis describes the synthesis and properties of three rigidified 
nucleic acid systems: the cyclo-2’-deoxynuclosides, ring expanded-cyclo-2’-
deoxynucleosides, and cyclo-2’-deoxy-5’-hydroxymethylnucleosides. The first 
rigidified nucleic acid system, cyclo-nucleoside, has an extra bond to lock the 
base with sugar moiety and maintains the 3’- to 5’-hydroxyl backbone 
linkage. 
 The next generation of rigidified nucleosides has an extended 7-
membered ring instead of the 6-membered ring present in the first 
generation. We hoped this would push the base closer to the helix center and 
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improve the decreased thermal stability in cyclo-nucleosides. The third 
system not only has the same linkage as the cyclo-nucleosides in the first 
system to restrict the base rotation, but also have an extra carbon (C6’) to 
give the backbone more flexibility which might better stabilize a double helix 
than the first generation. 
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2. Synthesis and Properties of Cyclo-2’-Deoxynucleic Acids  
2.1. Introduction 
DNA damage is a ubiquitous part of the cellular life cycle. Oxidative 
stress is particularly problematic for nucleic acids.  In many cases this stress 
is initiated by a free radical, commonly the hydroxyl radical (•OH). Hydroxyl 
radicals are generated by both exogenous agents such as carcinogenic 
molecules and ionizing radiation, as well as endogenous sources.1 DNA 
damage by free radicals is commonly termed as “oxidatively induced damage 
to DNA” in living cells. Such damage has been shown to result in 
mutagenesis, carcinogenesis, and aging.2 In terms of specific reactivity 
between these reactive oxygen species and DNA, two main adducts are likely:  
the addition of oxygen to the unsaturated bonds of the heterocyclic bases and 
abstraction of hydrogen atoms from the sugar backbone. H-abstraction has 
also been shown to occur at the methyl group of thymine, generating thymine 
dimers. As a result of these various damage pathways, a number of 
nucleobase and deoxyribose perturbations lead to single and double strand 
breaks, formation of abasic sites, DNA–protein and carbohydrate-nucleobase 
cross-links.3-7 
In this study we focus on 8,5’-cyclo-2’-deoxyadenosine and 6,5’-cyclo-2’-
deoxyuridine nucleosides (Figure 2.1.). 8,5’-cyclo-2’-deoxyadenosine 
represents a unique class of naturally occurring, helix-distorting DNA lesions 
that result in a second covalent linkage between the sugar and base moieties 
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of a single nucleoside.8 Unnatural 6,5’-cyclo-2’-deoxyuridine derivatives were 
also investigated, as they have similar structural features compared to the 
cyclo-deoxyadenosine moieties. 
 
 
 
 
 
 
Figure 2.1. The R and S diastereomers of 8,5’-cyclo-2’-deoxyadenosine and 
6,5’-cyclo-2’-deoxyuridine. 
 
 
 These lesions are initiated by H-abstraction at the C5’ by the hydroxyl 
radical species. This is followed by attack of the C5’-centered radical at the 
C8 of the purine base, leading to C8–C5’-cyclization. Subsequent oxidation of 
the resulting N7-centered radical results in the intramolecular cyclized 
product with a covalent bond between the C5’ and C8 positions of the purine 
nucleoside.9  
Both R and S diastereomers (Figure 2.1) are possible and although 
they result in similar puckering and distortion, the unique position of the 5’ 
OH causes them to have different properties.8, 10-13 It has been shown that the 
R-diastereomer is more prevalent under γ-radiation of an anaerobic water 
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solution of ss-DNA (single stranded-DNA), whereas the R/S ratio is reversed 
in favor of the S-diastereomer in ds-DNA (double stranded-DNA).14 Moreover, 
it is postulated that the R- and S-diastereomers of cyclo-dA may be 
recognized differently during nucleoside excision repair due to the 
stereospecificity of the repair enzymes. Studies have shown that the repair 
synthesis was more efficient in the plasmid substrate containing the R-
diastereomer than in the substrate with the S-diastereomer lesion.15, 16 These 
differences demand that each diastereomer needs to be prepared separately, 
which lead to our synthetic efforts in this chapter. 
 Cyclonucleoside lesions have major biological implications. These 
include blocking transcription and mutagenesis.8 Studies have proven that 
the lesions can alter the binding of transcription factors to their cognate DNA 
recognition elements.16 Cyclonucleosides can block the TATA binding protein 
(TBP) from associating with its target region, causing a transcriptional 
roadblock, which in turn shuts off gene expression. The exact mechanism of 
inhibition is not yet known.8 TBP binds in the minor groove, causing a major 
local conformational distortion.17 One of the reasons that nature may have 
chosen the TATA box instead of a GCGC box for transcriptional control is the 
ease of A·T minor groove deformation rather than the stronger G·C base-
pairs.17 Since cyclonucleosides block TBP binding, several factors may be 
operating: the rigidity imparted by the extra covalent bond could deform the 
secondary structure of the oligonucleotide duplex, the cyclonucleoside could 
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have more favorable entropic effect during the helix formation, or some 
combination of the two. 
 With stereochemically pure samples of these cyclic nucleosides, we 
hoped to address the question of whether or not this lesion results in stronger 
hydrogen bond interactions with its Watson-Crick pair.  The restricted 
flexibility of the C5’-C8 covalent bond might help to pre-organize and thereby 
reduce entropic loss while forming a base pair. On the other hand, if these 
lesions destabilize the duplex formation, it will confirm that the deformation 
caused by the extra bond overpowers the effect of the weak A•T base pair of 
the TATA box, and results in TBP inhibition. Since 6,5’-cyclo-2’-deoxyuridine 
features a similar lesion, it was synthesized by Dr. Hongchuan Yu to aid in 
the study of duplex stability. Due to synthetic constraints, the deoxyuridine 
monomer was produced instead of thymidine in order to retain aromaticity 
after introducing the C6-C5’ bond. 
This chapter presents efficient syntheses of the R and S diastereomers 
of 8,5’-cyclo-2’-deoxyadenosine. Then we incorporated these interesting 
nucleosides into DNA to study how the cyclo-linkage affects the stability of 
duplex formation.  
 
2.2. Synthesis of 8,5’-Cyclo-2’-Deoxyadenosine 
The focus of this study was to prepare both diastereomers based upon 
dA by introducing a second bond between the sugar and the heterocycle to 
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rigidify the nucleosides. We then wanted to incorporate the modified bases 
into the strands to investigate their behavior. These cyclonucleosides have a 
second bond between C5' and C8 for the 2’deoxyadenosine and C5' and C6 for 
2’-deoxyuridine.  The cross-links at these locations would result in glycosidic 
bond angles similar to those observed in double-stranded nucleic acids. The 
complete synthetic scheme of both R and S diastereomers of 8,5’-cyclo-2’-
deoxyadenosine phosphoramidites is shown below (Scheme 2.1). 
 
 
Scheme 2.1. Synthesis of the R and S diastereomers of 8,5’-cyclo-2’-
deoxyadenosine phosphoramidites. 
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The cyclo-2’-deoxyadenosine monomer was initiated from 2’-
deoxyadenosine (3) with the transient protection to selectively protect the N6-
amino group by benzoyl chloride (BzCl).18 2’-deoxyadenosine was treated with 
TMSCl first to protect 3’-OH and 5’-OH, then put on the benzoyl group on the 
N6 position, followed by NH4OH to remove the silyl groups. The product 
precipitated out from the aqueous solution after diethyl ether wash, no 
further purification needed. This is a well known and established step with a 
good yield. 
 
 
 
 
Scheme 2.2. Transient protection for 2’-deoxyadenosine. 
 
Compound 4 was then treated with p-toluenesulfonyl chloride to 
protect the primary hydroxyl group on the 5’ position, followed by protecting 
the 3’-OH with a triisopropylsilyl group. We established the conditions for 
silyl protection without using expensive silver nitrate as a catalyst. The high 
boiling point solvent, DMF, in this reaction could be easily removed by brine 
wash. 
 
 
 
Scheme 2.3. Synthesis of compound 5 and compound 6.  
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The synthesis of compound 8, 8,5’-cyclo-2’,5’-dideoxyadenosine, was 
carried out in three steps. Substitution of the 5'-tosyl by iodide to obtain the 
5’-iodo compound 7 permitted a zinc-mediated cyclization to generate the 
cyclized product. After the cyclization, the product had to be treated with 
tetrachloro-p-benzoquinone to regenerate the aromaticity on the nucleobase 
to get the rigidified cyclo-nucleoside 8. 
 
 
 
 
 
Scheme 2.4. Synthesis of compound 7 and compound 8. 
 
The next step was to generate the 5’-OH to afford the 3’ to 5’ linkage as 
found in nature. Compound 8 was oxidized at the C5’ position with SeO2 in 
dioxane to yield the ketone compound 9, which upon reduction with NaBH4 
formed exclusively the S-diastereomer (compound 10S). We proposed this was 
due to the steric hinderance of the cyclized structure that only allowed  
NaBH4 to react from the less hindered position. 
 
 
 
 
 
Scheme 2.5. Synthesis of compound 9 and compound 10S. 
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  To obtain the R diastereomer, 10S was first treated with mesyl  
chloride to put on a good leaving group on C5’ position and then inverted with 
sodium hydroxide to obtain 10R in high yields. Here, it was important to 
carefully control the concentration of the sodium hydroxide to avoid the de-
benzoylation on the N6 position. 
 
 
 
 
Scheme 2.6. Synthesis of compound 11 and compound 10R. 
 
From this point forward the two diastereomers were processed in 
parallel. The newly formed 5’ hydroxyls of both the R and S diastereomers 
were unable to be protected with the standard 4,4’-dimethoxytrityl chloride 
(DMTrCl) protecting group due to the steric hindrance in these rigidified 
nucleosides.  Instead we opted to use ethyl vinyl ether to form 1-ethylethoxy 
protected 12S and 12R. The 1-ethylethoxy is an acid labile protecting group 
which has similar deprotecting conditions as DMTrCl on the DNA 
synthesizer. The ethyl vinyl ether protection resulted in two additional 
diastereomers at the newly formed methyl position, which co-migrated during 
silica gel chromatography. 
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Scheme 2.7. Synthesis of compound 12S and 12R. 
 
The final steps involved removal of the 3' silyl protecting group by 
fluoride ion (tetra-n-butylammonium fluoride, TBAF) and conversion to the 
3-phosphoramidites (14S, 14R).  The presence of the two phosphorus 
diastereomers and the two 1-ethylethoxy protected diastereomers could be 
confirmed by the presence of four phosphorus resonances in the final R and S. 
The overall yield for the 10-step synthesis of the S diastereomer is 9.0 %, and 
for the 12-step synthesis of the R diastereomer is 7.5 %; it is around 80 % 
yield in terms of average stepwise for both diastereomers. 
 
 
 
 
 
 
 
 
Scheme 2.8. Synthesis of compound 13S , 13R and compound 14S , 14R. 
29 
 
The synthesis of the 3-phosphoramidites for the cyclo-deoxyuridine 
(cyclo-dU) derivatives were completed by Dr. Hongchuan Yu using an 
established protocol19 with the exception of the chlorination reaction on the 
C5 position, which was more efficiently accomplished using CAN (cerium (IV) 
ammonium nitrate)/LiCl in 88% yield. The details of that synthesis can be 
found in his thesis.20 
 
 
 
 
 
Figure 2.2. The R and S diastereomers of 6,5’-cyclo-2’-deoxyuridine 
phosphoramidites. 
 
 
 
2.3. Crystal Structures of nucleosides and Thermal Denaturation Studies of 
the Sequences Containing Modified Nucleosides 
The four cyclonucleosides, were incorporated into 12-mer or 14-mer 
sequences containing a core d(AAAA)/d(TTTT) sequence. In the purified 
oligos, the presence of the cyclonucleosides had no effect on the activity of 
nuclease enzymes, allowing us to digest the oligos and confirm the 
incorporation by HPLC. 
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After synthesizing these compounds and obtaining crystal structural 
information (Figure 2.3), it became clear that these nucleosides would not 
enhance duplex stability.  The reasoning behind this is that the C5’-C8 (dA) 
and C5’-C6 (dU) bonds “pulls” the heterocycle away from the center of the 
DNA double helix preventing it from forming a Watson-Crick base pair. 
 
 
 
 
 
 
Figure 2.3. The crystal structures of 10R, with protecting groups hidden, and 
deprotected S – diastereomer for cyclo-dU overlayed with 2’-dA and 2’-dU 
(green structures).21, 22 
 
Torsion angles can help to explain the nature of the duplexes 
containing rigid nucleosides.  By introducing the bond between C8 and C5’ in 
cyclo-2’-deoxyadenosine and C6 and C5’ in cyclo-2’-deoxyuridine the glycosidic 
torsion angles, χ, became fixed at -146.7o and -152.1o respectively.  The dA-dT 
core in the Dickerson Dodecamer has χ values ranging from near -80o to near 
-115o while the corresponding RNA sequence exhibits χ values around -160o. 
These values suggest that the fused nucleosides might be better 
accommodated in an RNA A-like duplex; however even these RNA/DNA 
heteroduplexes lack stability (see Table 2.1, entry 16 and 17). 
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Table 2.1. Thermal denaturation experiments of the native sequences (entry 
1, 6, and 15) and modified sequences. Entry 15 – 17 are DNA/RNA 
heteroduplexes pairs. Cyclonuclosides are denoted by underline and bold text. 
Isotherms are attached in Chapter 2.7, Figure 2.8 – Figure 2.21. 
1 =8,5’(S)-cyclo-2’-deoxyadenosine; 2 =8,5’(R)-cyclo-2’-deoxyadenosine; 
3 =6,5’(S)-cyclo-2’-deoxyuridine; 4 =6,5’(R)-cyclo-2’-deoxyuridine 
*=Duplex formation was not observable. 
 
 
Entry Sequence TM (oC) 
1 5’-d(C C G G A A A A C G C C)/5’-d(G G C G T T T T C C G G) 49 
2 5’-d(C C G G AS 1 A AS A C G C C)/5’-d(G G C G T T T T C C G G) 40 
3 5’-d(C C G G AR 2 A AR A C G C C)/5’-d(G G C G T T T T C C G G) 36 
4 5’-d(C C G G A A A A C G C C)/5’-d(G G C G US 3 T US T C C G G) 28 
5 5’-d(C C G G A A A A C G C C)/5’-d(G G C G UR 4 T UR T C C G G) 36 
 
6 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T T T T T T C C G G) 51 
7 5’-d(C C G G A AS AS AS AS A C G C C)/5’-d(G G C G T T T T T T C C G G) 17 
8 5’-d(C C G G A AR AR AR AR A C G C C)/5’-d(G G C G T T T T T T C C G G) 28 
9 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T US US US US T C C G G) 28 
10 5’-d(C C G G A A A A A A C G C C)/5’-d(G G C G T UR UR UR UR T C C G G) 16 
11 5’-d(C C G G A AS AS AS AS A C G C C)/5’-d(G G C G T US US US US T C C G G) 14 
12 5’-d(C C G G A AS AS AS AS A C G C C)/5’-d(G G C G T UR UR UR UR T C C G G) * 
13 5’-d(C C G G A AR AR AR AR A C G C C)/5’-d(G G C G T US US US US T C C G G) * 
14 5’-d(C C G G A AR AR AR AR A C G C C)/5’-d(G G C G T UR UR UR UR T C C G G) * 
 
15 5’-d(C C G G A A A A C G C C)/5’-G G C G U U U U C C G G 43 
16 5’-d(C C G G AS A AS A C G C C)/5’-G G C G U U U U C C G G 29 
17 5’-d(C C G G AR A AR A C G C C)/5’-G G C G U U U U C C G G 30 
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The torsion angle for the C4’-C5’ bond () is also problematic.  The  
torsion angle prefers a value close to 70o for RNA and a value near 40o for 
DNA.  In these conformations the 5’-O is positioned above the sugar and 
angled toward the heterocycle. In the case of the modified nucleosides, that 
position is occupied by the C8-C5’ bond in cyclo-2’-deoxyadenosine or the C6-
C5’ bond in cyclo-2’-deoxyuridine. The fused 5’-OH is left in a position 
normally inhabited by the C5’ hydrogens. The S diastereomer results in a  
torsion angle near -50o while the R produces a torsion angle of about -170o . 
 
 
 
 
 
 
Figure 2.4. An overhead view of a cyclonucleoside highlighting the relevant 
torsion angles. 
 
 
 The results of thermal denaturation studies fit in with our hypothesis. 
In table 2.1, we firstly incorporated two modified bases into the middle of the 
sequence alternatively (entry 2 – 5), and found destabilization. Then we 
incorporated four modified bases into the middle of the sequence 
consecutively (entry 7 – 14) to investigate if there was cooperative 
33 
 
stabilization between these cyclo-nucleic acids. The results showed that these 
consecutive bases distorted the structure more and in some modified base – 
modified base pairs (entry 12 – 14) the TM could not be found. 
 
2.4. Conclusions 
Our effort towards preparing pure diastereomers of nucleosides of 
cyclo-2’-deoxyadenosine and cyclo-2’-deoxyuridine in appreciable yields has 
been successful. We incorporated these nucleosides into DNA sequences and 
found that the TM in most of the cases is reduced. These results are in 
accordance with theoretical studies performed in the labs of John Miller.12 
Our data proves that cyclonucleoside lesions destabilize duplex formation. 
This supports the hypothesis that duplex deformation caused by this lesion 
overpowers the effects of the weaker TATA box base pairing, thus inhibiting 
TBP binding. Our crystal structures show that the nucleobase is “pulled” 
back from its Watson and Crick position, explaining why these molecules 
form weaker hydrogen bonds as a base pair. These compounds are of 
continued interest due to the fact that they are resistant towards enzymatic 
repair and may be valid drug targets.23 
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2.5. Experimental 
2.5.1. General Information 
Reagents were purchased from Sigma-Aldrich, Acros, Oakwood, Glen 
Research, Lancaster, MP Biomedical, Chem-Impex International, Fisher, 
Chem Genes and Molekula. Flash column were performed using Dynamic 
Adsorbents silica gel (60 Å, particle size 32-63 m) and TLC monitoring with 
TLC Silica Gel with F-254 Indicator (Dynamic Adsorbents). TLCs were 
visualized by 260nm UV light and stained by 10% sulfuric acid. All reactions 
were carried out under a nitrogen atmosphere with dry solvent under 
anhydrous conditions unless indicated otherwise. Dry tetrahydrofuran (THF), 
diethyl ether (Et2O), N,N-dimethylformamide (DMF), pyridine (pyr), 
acetonitrile (MeCN), and dichloromethane (DCM) were obtained by passing 
commercially available pre-dried, oxygen-free formulations through activated 
alumina columns. Dry ethanol was purchased from Sigma-Aldrich and used 
directly. NMR spectra were taken by Varian VNMRS400, VNMRS500, or 
INOVA 500 instruments and calibrated using residual undeuterated solvent 
(CDCl3: δ H = 7.24 ppm, δ C = 77.23 ppm, DMSO-d6: δ H = 2.50 ppm, δ C = 
39.51 ppm). Abbreviations of multiplicities were designated as follow: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet b = broad. High-
resolution mass spectra (HRMS) were recorded on a Waters LCT or JEOL 
AccuTOF mass spectrometer using ESI (electrospray ionization) or DART 
(direct analysis in real time). UV spectra were acquired by Beckman 
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(Fullerton, CA) DU650 spectrophotometer.  HPLC was performed on Waters 
(Milford, MA) Delta 600 controllers with a 2487 dual wavelength detector. 
RNA oligomers were purchased from Integrated DNA Technologies 
(Coralville, IA). Polyacrylamide Gel Electrophoresis was performed by using 
a Hoefer Scientific (San Francisco, CA) apparatus. Gel imaging was 
performed on Bio-Rad (Hercules, CA) FXpro Molecular Imager with ethidium 
bromide staining or Kodak-K radioisotope screens. The X-ray diffraction data 
were collected using a Bruker Kappa Apex Duo fully automated single crystal 
diffractometer, duo wavelength system with sealed molybdenum tube and 
high brightness copper source.  
 
 
2.5.2. DNA Synthesis and Purification 
 The native and modified DNA oligomers were prepared by Applied 
Biosystems 394 DNA/RNA synthesizer using standard solid phase 
phosphoramidite techniques and the reagents purchased from Glenn 
Research (Sterling, VA). The native DNA strands were performed under 
standard 1 μmole synthesis protocol with 2 minutes waiting time during the 
base coupling; the sequences with modified nucleosides incorporated were 
using the same protocol with 1 hour waiting time. All the native sequences 
were giving over 95% average stepwise yield; the yield for the syntheses with 
modified bases were not be able to be monitored since the protecting group on 
the 5’-O is not UV active. 
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All oligos were deprotected and cleaved off from the solid supports by 
12 hours treatment with concentrated ammonia at 55 oC water bath. The 
solutions were decanted and evaporated by speedvac, then redissolved in 5-8 
mL of DI water for HPLC purification. The HPLC purification was 
accomplished by self-packed Oligo R3 column (0.46 cm × 10 cm), and the 
mobile phase buffer A: 50 mM TEAA (triethylammonium acetate, pH 7.0) 5% 
acetonitrile, Buffer B: 50 mM TEAA (pH 7.0) 70% acetonitrile. The program 
of the running gradient is showing below in Table 2.2. 
 
Table 2.2. Gradient for purifying oligos on Oligo-R3 column. 
 
 
 
 
 
 
 
 
 
 The next step was removing the trityl protecting group on the 5’-end by 
treating the oligos in 80% acetic acid for 30 minutes then desalted through 
Sephade G-10 column and lyophilized after removing the acetic acid by rotary 
evaporator. The oligonucleotides were redissolved in D.I. water and 
determined the concentration by UV absorbance. Further purification of the 
oligos was accomplished by 20% denaturing acrylamide gel. 
 
 
Time (min) Flow Rate (mL/min) Buffer A (%) Buffer B (%) 
0                  3 (Initial) 100 0 
25 3 50 50 
30 3 0 100 
40 3 0 100 
41 3 100 0 
61 3 100 0 
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2.5.3. Enzymatic Digestion 
In order to prove the incorporation of the modified nucleotides was 
successful, we firstly synthesized the Dickerson dodecamer24, d(CGC GAA 
TTC GCG), with two R- diastereomer of cyclo-dA. Then we performed the 
enzymatic digestion experiments to clarify the composition of the nucleotides.  
A mixture of 3 μL of alkaline phosphatase, 3 μL of phosphodiesterase I, 
4 μL of nuclease P1, 10 μL of 10X alkaline phoaphatase buffer, 10 μL of 1.0 M 
MgCl2, and 70 μL of water was added to a eppendorf tube containing 2 
nmoles of the DNA oligomer. The mixture was left at 37 oC overnight, then 
cooled to room temperature. The digested nucleoside mixture was analyzed 
by reverse-phase analytical HPLC with a self-packed C18 column (0.46 cm × 
25 cm, 5 μm 100 Å resin). Mobile phase buffer A: 100 mM TEAA buffer (pH 
7.0). Mobile phase buffer B: acetonitrile. Flow rate: 1 mL/min. Gradient of the 
elution: 0-25% in 30 min and 25-100% in 10 min. The mixtures were 
monitored by UV at 260 nm. HPLC traces were attached in Chapter 2.7, 
Figure 2.7.  In modified sequence, there is no dA on the strand but a new 
peak with the integral area represented 2 bases. Assuming the cyclo-dA 
possesses a similar extinction coefficient as the natural base, the result 
represented the phosphoramidite of the cyclo-dA is working perfectly on the 
DNA synthesizer (Table 2.3). 
 
 
38 
 
Table 2.3. Enzymatic digestion results.  
 
Control Sequence 5’-d(CGC GAA TTC GCG)-3’ 
Nucleoside Area ε at 260 
nm 
Corrected 
Area 
Normalized 
Area 
total 
dC 79 7300 0.011 1.000 2.0 
dG 134 11700 0.011 1.058 2.1 
dT 50 8800 0.006 0.525 1.1 
dA 77 15400 0.005 0.462 0.9 
Cyclo-dA 0 15400 0 0 0 
 
Modified Sequence 5’-d(CGC GARAR TTC GCG)-3’ 
Nucleoside Area ε at 260 nm Corrected 
Area 
Normalized 
Area 
total 
dC 110 7300 0.015 1.000 2.0 
dG 171 11700 0.015 0.970 1.9 
dT 89 8800 0.010 0.671 1.3 
dA 0 15400 0 0 0 
Cyclo-dA 126  15400* 0.008 0.543 1.1 
*Using the same extinction coefficient as dA. 
 
 
 
2.5.4. Thermal Denaturation Studies 
All UV melting experiments were carried out in 20 mM sodium 
phosphate buffer at pH 7.0 with 100 mM or 1 M sodium chloride using AVIV 
Biomedical Inc. (Lakewood, NJ) spectrophotometer model 14DS UV-Vis with 
a temperature controller and five-sample holder. Samples (0.5 μM for each 
complementary sequence, 1.0 μM for total) were heated under 95 oC water 
bath for 5 min and the water bath allowed to cool to room temperature then 
cooled to 4 oC in the coldroom. Samples were place in a 1 cm path length 
quartz cell with stopper and the denaturation experiments were performed 
between 4 oC and 95 oC. Data was collected every degree under 260 nm. The 
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Tm values were determined by utilizing the first derivative from the melting 
profile with Origin and Microsoft Excel. The TM isotherms are attached in 
chapter 2.7, figure 2.7 to figure 2.20. 
 
 
 
2.5.5. Thermal Circular Dichroism studies 
All Circular Dichroism experiments were carried out in 20 mM sodium 
phosphate buffer at pH 7.0 with 100 mM or 1 M sodium chloride using AVIV 
Biomedical Inc. (Lakewood, NJ) Circular Dichroism spectrophotometer model 
420 with a temperature controller. Samples preparation: single-stranded 
samples (concentration of oligomers: 8 μM) were performed the experiment 
directly. Double-stranded samples (total concentration of oligomers: 8 μM) 
were heated under 95 oC water bath for 5 min and the water bath allowed to 
cool to roomtemperature then cooled to 4 oC in the coldroom. Samples were 
place in a 1 cm path length quartz cell with stopper and the denaturation 
experiments were performed at 25 oC. CD spectra are attached in Chapter 
2.7, Figure 2.21 and Figure 2.22. 
 
2.5.6. Crystallization of Compound 10R 
 50 mg of compound 10R was firstly dissolved in 0.25 mL of 
dichloromethane in a 6 X 50 mm disposable culture tube at room 
temperature. The culture tube was then sitting in a capped 20 mL sample 
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vial which was filled with 2 mL of hexane. The whole assembly was kept 
undisturbed to obtain the crystals. The X-ray data and crystal structure were 
collected and solved by Dr. Bo Li, Director of X-ray Crystallography Center at 
Boston College. The Structural data and information are attached in Chapter 
2.7, Figure 2.5 - 2.6 and Table 2.4 – 2.10. 
 
 
 
2.5.6. Synthesis 
 
Compound 4: N-benoyl-2’-deoxyadenosine 
 2’-deoxyadenosine (10.0 g, 40.0 mmol) was dissolved in 
dry pyridine (400 mL) and cooled by ice bath. 
Chlorotrimethylsilane (26.4 mL, 208 mmol) was added to the 
solution and the mixture was kept on ice for 30 minutes. Benzoyl chloride 
(30.0 mL, 260 mmol) was added at 0 oC and the reaction mixture warmed to 
ambient temperature and stirred for 2 hours.  The flask was cooled back to 0 
oC and the reaction quenched with water (80 mL). After 15 min concentrated 
aqueous ammonium hydroxide (80 mL) was added and the mixture was kept 
on ice for another 30 minutes. Solvents were removed under reduced pressure 
and the residue dissolved in water (300 mL) and washed twice with diethyl 
ether (200 mL each). Compound 4 precipitated from the aqueous solution as a 
white solid after sitting at 4 oC overnight (12.5 g, 88%). TLC Rf : 0.17 
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(DCM/MeOH 83:17). 1H NMR (400 MHz; CD3OD): δ 2.49 (m, 1H), 2.84 (m, 
1H), 3.74-3.86 (m, 2H), 4.07 (d, 1H), 6.55 (t, 1H), 7.54 (t, 2H), 7.63 (t, 1H), 
8.07 (d, 2H), 8.63 (s, 1H), 8.69 (m, 1H). 13C NMR (100MHz; CD3OD): δ 41.6, 
63.4, 72.8, 86.8, 89.9, 125.6, 129.6, 129.9, 134.0, 135.1, 144.7, 151.3, 153.0, 
168.3. ESI-MS (pos.): 356.1353 [M+H]+ (HSMS calc. 356.1359). 
 
Compound 5: N-Benzoyl-5’-tosyl-2’-deoxyadenosine 
 Compound 4 (10.2 g, 28.7 mmol) was dissolved in dry 
pyridine (140 mL) and cooled to 0 oC.  p-tosylsulfonyl chloride 
(8.20 g, 43.0 mmol) was added and the reaction mixture was 
allowed to warm to ambient temperature and stir overnight. The reaction 
was quenched with water at 0 oC and solvents were removed under reduced 
pressure. The residue was dissolved in DCM and washed with water 3 times 
and once with brine. The organic layer was dried over sodium sulfate and 
concentrated in a rotary evaporator. The crude product was purified by flash 
chromatography (DCM/MeOH 95:5) to yield the 5 as a white solid (12.1 g, 
83%). TLC Rf : 0.32 (DCM/MeOH 90:10). 1H NMR (400 MHz; CDCl3): δ 2.43 
(s, 3H), 2.49 (d, 1H), 2.58 (m, 1H), 2.97 (m, 1H), 4.23-4.3 (m, 3H), 4.83 (bm, 
1H), 6.49 (t, 1H), 7.31 (d, 2H), 7.54 (t, 2H), 7.63 (t, 1H), 7.74 (d, 2H), 8.03 (dd, 
2H), 8.18 (s, 1H), 8.75 (s, 1H), 8.98 (s, 1H). 13C NMR (100 MHz; CD3OD): δ 
41.6, 63.4, 72.8, 86.8, 89.9, 125.6, 129.6, 129.6, 129.9, 129.9, 134.0, 134.2, 
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134.3, 135.1, 144.7, 146.5, 151.3, 153.0, 153.1, 168.3. ESI-MS (pos.): 510.1455 
[M+H]+ (HSMS calc. 510.1447). 
 
Compound 6: N-Benzoyl-3’-triisopropylsilyl-5’-tosyl-2’-deoxyadenosine 
 Compound 5 (5.60 g, 11.0 mmol), imidazole (2.30 g, 
33.4 mmol), and silver nitrate (3.78 g, 22.2 mmol) were 
dissolved in dry pyridine (56 mL) and cooled to 0 oC.  
Triisopropylsilyl chloride (4.70 ml, 22.0 mmol) was added and the reaction 
was warmed to ambient temperature. After stirring for two days the reaction 
was quenched with water while on an ice bath. The solvents were removed 
under reduced pressure and the residue dissolved in dichloromethane and 
washed with water three times and once with brine.  The organic layer was 
dried over sodium sulfate and concentrated under vacuum.  The crude 
product was purified by flash chromatography (DCM/MeOH 97:3) to yield 6 
as a white (5.2 g, 72%). TLC Rf : 0.65 (DCM/MeOH 97:3). 1H NMR (400 MHz; 
CDCl3): δ 1.07-1.12 (m, 21H), 2.42 (s, 3H), 2.47-2.51 (m, 1H), 2.93 (m, 1H), 
4.22 (s, 1H), 4.19-4.3 (m, 2H), 4.73 (t, 1H), 6.47 (t, 1H), 7.29 (d, 2H), 7.52 (t, 
2H), 7.6 (q, 1H), 7.74 (d, 2H), 8.03 (d, 2H), 8.20 (s, 1H), 8.73 (s, 1H). 13C NMR 
(100 MHz; CDCl3): δ 11.9, 17.9, 21.6, 40.3, 68.8, 73.0, 85.0, 85.4, 123.4, 125.8, 
127.9, 128.8, 129.9, 132.2, 132.8, 133.4, 141.9, 145.2, 149.4, 151.4, 152.1, 
164.7. ESI-MS (pos.): 666.2762 [M+H]+ (HSMS calc. 666.2782). 
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Compound 7: N-Benzoyl-3’-triisopropylsilyl-5’-iodo-2’-deoxyadenosine 
 Compound 6 (4.26 g, 6.40 mmol) and sodium iodide 
(3.84 g, 2.56 mmol) were dissolved in dry acetone (32 mL) and 
refluxed for four hours. The solid suspension filtered through 
Celite and the filtrate was concentrated under vacuum. The crude was 
purified by flash chromatography (DCM/MeOH 97.5/2.5) to yield 7 as a white 
foam (3.9 g, 98%) TLC Rf : 0.42 (DCM/MeOH 97.5/2.5). 1H NMR (400 MHz; 
CDCl3): δ 1.04-1.14 (m, 21H), 2.23 (s, 1H), 2.47 (m, 1H), 3.08 (m, 1H), 3.36-
3.53 (m, 2H), 4.07 (m, 1H), 4.70 (t, 1H), 6.44 (t, 1H), 7,47 (t, 2H), 7.56 (t, 1H), 
7.99 (d, 2H), 8.24 (s, 1H), 8.74 (s, 1H), 9.22 (s, 1H). 13C NMR (100 MHz; 
CDCl3): δ 6.3, 12.0, 18.0, 39.9, 75.4, 85.2, 86.7, 123.7, 127.8, 128.8, 132.7, 
133.6, 142.2, 149.6, 151.4, 152.5, 164.6. ESI-MS (pos.): 622.1715 [M+H]+ 
(HSMS calc. 622.1710). 
 
Compound 8: N-Benzoyl-3’-triisopropylsilyl-8,5’-cyclo-2’,5’-dideoxyadenosine 
 Compound 7 (1.25 g, 2.00 mmol) and zinc powder (2.63 g, 
40.2 mmol) were dissolved in dry pyridine (70 mL) and heated to 
80 oC for 4 hours. The zinc powder was removed by filtration and 
the filtrate was concentrated under reduced pressure. The residue and 
tetrachloro-1,4-benzoquinone (0.490 g, 2.00 mmol) were dissolved in benzene 
(40 mL) and refluxed for 2 hours. The solvent was then evaporated under 
vacuum and the crude product was purified by flash chromatography 
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(DCM/MeOH 98:2) to yield the cyclized product as a yellow foam (0.42 g, 
42%).  TLC Rf : 0.32 (DCM/MeOH 97:3). 1H NMR (400 MHz; CDCl3): δ 0.98-
1.07 (m, 21H), 2.36 (m, 1H), 2.66 (m, 1H), 3.11 (d, 1H), 3.58 (m, 1H), 4.51 (m, 
1H), 4.80 (d, 1H), 6.58 (d, 1H), 7.50 (t, 2H), 7.59 (t, 1H), 7.99 (t, 2H), 8.68 (s, 
1H), 8.74 (s, 1H). 13C NMR (100 MHz; CDCl3): δ 11.8, 17.8, 31.2, 48.1, 75.3, 
83.2, 84.8, 127.8, 128.8, 132.8, 133.5, 146.8, 147.4, 148.1, 148.3, 151.8, 164.5. 
ESI-MS (pos.): 516.2425 [M+Na]+ (HSMS calc. 516.2407). 
 
Compound 9:  N-Benzoyl-3’-triisopropylsilyl-5’-keto-8,5’-cyclo-2’-
deoxyadenosine 
 Compound 8 (0.186 g, 0.377 mmol) and selenium 
dioxide (90.0 mg, 0.814 mmol) were dissolved in 1,4-dioxane 
(50 mL) and refluxed for 1 hour. The reaction mixture was 
filtered through Celite and the solvent removed under vacuum.  The product 
was purified by flash chromatography (DCM/MeOH 97:3) to yield 9 as a 
yellow foam (0.170 g, 89%).  TLC Rf : 0.23 (DCM/MeOH 95:5). 1H NMR (400 
MHz; CDCl3): δ 1.02-1.07 (m, 21H), 2.14 (s, 1H), 2.56 (m, 1H), 2.72 (m, 1H), 
4.76 (dd, 1H), 4.96 (s, 1H), 6.83 (d, 1H), 7.52 (t, 2H), 7.61 (t, 1H), 7.97 (d, 2H), 
8.92 (s, 1H), 9.19 (s, 1H). 13C NMR (100 MHz; CDCl3): δ 11.8, 17.8, 44.8, 72.7, 
85.9, 92.3, 122.9, 127.9, 129.0, 133.2, 140.8, 147.9, 148.3, 152.3, 156.1, 164.3, 
184.6. ESI-MS (pos.): 530.2186 [M+Na]+ (HSMS calc. 530.2200). 
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Compound 10S : N-Benzoyl-3’-triisopropylsilyl-8,5’(S)-cyclo-2’-deoxyadenosine 
 Compound 9 (0.454 g, 0.890 mmol) was dissolved in 
methanol (27 mL) and cooled to 0 oC, 0.1 M sodium 
borohydride aqueous solution (5 mL) was added and the 
stirring reaction was allowed to warm to ambient temperature.  After 1.5 
hours the reaction was neutralized with 1N hydrochloric acid and the 
solvents were removed under vacuum.  The crude product was purified by 
flash chromatography (DCM/MeOH 95:5) to yield 10S as a white powder 
(0.425 g, 93%).  TLC Rf: 0.22 (DCM/MeOH 97:3). 1H NMR (400 MHz; CDCl3): 
δ 0.95-1.03 (m, 21H), 2.31 (m, 1H), 2.55 (s, 1H), 4.56 (d, 1H), 4.88 (q, 1H), 5.03 
(s, 1H), 5.46 (d, 1H), 6.50 (d, 1H), 7.50 (t, 2H), 7.59 (t, 1H), 7.97 (d, 2H), 8.69 
(s, 1H), 8.93 (s, 1H). 13C NMR (100 MHz; CDCl3): δ 11.8, 17.9, 47.0, 64.8, 69.3, 
85.5, 86.4, 122.6, 127.8, 128.9, 132.9, 133.4, 148.6, 149.9, 151.5, 152.5, 164.8. 
ESI-MS (pos.): 510.2534 [M+H]+ (HSMS calc. 510.2537). 
 
 
Compound 10R : N-Benzoyl-3’-triisopropylsilyl-8,5’(R)-cyclo-2’-
deoxyadenosine 
 Compound 11 (0.370 g, 0.630 mmol) was dissolved in a 
dimethylformamide/water mixture (50:17.6 mL) and 0.1 M 
sodium hydroxide (7.55 mL) was added over 5 hours and after 
complete addition stirred for an additional hour. The reaction mixture was 
neutralized with 1 N hydrochloric acid and the solvents were removed under 
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vacuum.  The crude product was purified by flash chromatography 
(DCM/MeOH 97:3) to yield 10R as a white powder (0.26 g, 80%). TLC Rf : 0.17 
(dichloromethane/methanol = 30/1). 1H NMR (400 MHz; CDCl3): δ 1.01-1.08 
(m, 21H), 2.35 (m, 1H), 2.54 (m, 1H), 4.42 (q, 1H), 4.67 (s, 1H), 4.94 (d, 1H), 
6.19 (s, 1H), 6.61 (d, 1H), 7.53 (dt, 2H), 7.59 (dt, 1H), 8.07 (dd, 2H), 8.75 (s, 
1H), 9.32 (s, 1H). 13C NMR (100 MHz; CDCl3): δ 11.8, 17.9, 45.9, 65.8, 71.7, 
85.2, 89.0, 121.6, 128.2, 128.8, 132.9, 133.5, 148.0, 149.1, 149.5, 153.1, 165.0. 
ESI-MS (pos.): 532.2351 [M+Na]+ (HSMS calc. 532.2356). 
 
Compound 11: N-Benzoyl-3’-triisopropylsilyl-5’-mesyl-8,5’(S)-cyclo-2’-
deoxyadenosine 
Compound 10S (0.570 g, 0.570 mmol) was dissolved in 
pyridine (5.7 mL) and methanesulfonyl chloride (110 μL, 1.43 
mmol) was added at 0 oC.  The reaction was slowly warmed 
ambient temperature and stirred overnight before being quenched  with 
water. The solvents were removed under vacuum and the residue was 
dissolved in DCM and washed with water 3 times and once with brine. After 
removing the DCM under reduced pressure, the crude product was purified 
by flash chromatography (DCM/MeOH 97.5:2.5) to yield the mesylated 
product as a white powder (0.31 g, 91%). TLC Rf : 0.38 (DCM/MeOH 97.5:2.5). 
1H NMR (400 MHz; CDCl3): δ 1.01-1.10 (m, 21H), 2.40 (m, 1H), 2.66 (m, 1H), 
3.57 (s, 3H), 4.89-4.93 (m, 2H), 6.12 (d, 1H), 6.55 (d, 1H), 7.52 (t, 2H), 7.61 (t, 
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1H), 7.94 (d, 2H), 8.68 (s, 1H), 8.73 (s, 1H). 13C NMR (100 MHz; CDCl3): δ 
11.8, 17.9, 40.0, 46.7, 70.1, 70.4, 85.1, 85.5, 122.8, 127.8, 129.0, 133.0, 133.4, 
145.2, 149.2, 150.0, 152.9, 164.5. ESI-MS (pos.): 610.2136 [M+Na]+ (HSMS 
calc. 610.2132). 
 
Compound 12S and 12R 
N-Benzoyl-3’-triisopropylsilyl-5’-(1-ethoxyethyl)-8,5’(S)-cyclo-2’-
deoxyadenosine and N-Benzoyl-3’-triisopropylsilyl-5’-(1-ethoxyethyl)-8,5’(R)-
cyclo-2’-deoxyadenosine 
 Compound 10S (0.150 g, 0.300 mmol) and 
pyridinium-p-toluenesulfonate (75.0 mg, 0.300 mmole) were 
dissolved in dichloromethane (3 mL) followed by the 
addition of ethyl vinyl ether (0.175 mL, 1.80 mmol) and stirred overnight at 
ambient temperature. The solvents were removed under vacuum and the 
crude product was purified by flash chromatography (DCM/MeOH/Et3N 
96:3:1) to yield 12S as a yellow foam (0.12 g, 86%). TLC Rf : 0.3 (DCM/MeOH 
97:3). 1H NMR (400 MHz; CDCl3): δ 1.04-1.26 (m, 21H), 1.25-1.30 (bm, 3H), 
1.50 (dd, 3H, J = 40.2, 5.4 Hz), 2.34 (m, 1H), 2.60 (m, 1H), 3.62-3.88 (bm, 2H), 
4.74 (dd, 1H, J = 18.0, 6.4 Hz), 4.95 (m, 1H), 5.21-5.56 (dq, 1H, J = 132.4, 5.2 
Hz), 5.33 (dd, 1H, J = 14.4, 6.0 Hz), 6.52 (q, 1H), 7.52 (m, 2H), 7.61 (dt, 1H), 
7.97 (m, 2H), 8.74 (s, 1H). ESI-MS (pos.): 582.3085 [M+H]+ (HSMS calc. 
582.3112). 
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 12R was prepared using the same procedure as 12S 
with the exception of chromatographic conditions 
(DCM/MeOH/Et3N 96.4/2.5/1) to yield the product as a 
yellow foam (0.12 g, 90%). TLC Rf : 0.45 (DCM/MeOH 97:3). 1H NMR (400 
MHz; CDCl3): δ 1.01-1.08 (m, 21H), 1.21-1.28 (bm, 3H), 1.40 (dd, 3H, J = 60.8, 
5.6 Hz), 2.32 (m, 1H), 2.48 (m, 1H), 3.59-3.77 (bm, 2H), 4.38 (q, 1H), 4.82 (d, 
1H), 4.87 (s, 1H), 5.14-5.44 (dq, 1H, J = 109.6, 5.6 Hz), 6.60 (d, 1H), 7.52 (dt, 
2H), 7.60 (dt, 1H), 7.97 (dd, 2H), 8.76 (s, 1H), 8.86 (d, 1H). ESI-MS (pos.): 
604.2913 [M+Na]+ (HSMS calc. 604.2931). 
 
Compound 13S and 13R 
N-Benzoyl -5’-(1-ethoxyethyl)-8,5’(S)-cyclo-2’-deoxyadenosine (13S) and N-
Benzoyl-5’-(1-ethoxyethyl)-8,5’(R)-cyclo-2’-deoxyadenosine (13R) 
 Tetra-n-butylammonium fluoride (1.0 M solution in 
THF, 0.50 mL) was added to a solution of 12S (0.132 g, 
0.227 mmol) in THF (1.5 mL) at ambient temperature and 
stirred for one hour. The solvent was removed under reduced pressure and 
the crude product was purified by flash chromatography (DCM/MeOH/Et3N 
96.5:2.5:1) to yield the 13S as a white powder in quantitative yield (95 mg). 
TLC Rf : 0.22 (DCM/MeOH 97:3). 1H NMR (400 MHz; CDCl3): δ 1.07-1.27 (dt, 
3H), 1.25-1.48 (dd, 3H), 2.32 (m, 1H), 2.59-2.66 (bm, 3H), 3.62 (m, 1H), 3.81 
(m, 1H), 4.84 (d, 1H), 4.93 (q, 1H), 5.28 (d, 1H), 5.33 (q, 1H), 6.50 (d, 1H), 7.52 
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(dt, 2H), 7.60 (dt, 1H), 7.97 (dd, 2H), 8.74 (s, 1H). ESI-MS (pos.): 426.1780 
[M+H]+ (HSMS calc. 426.1777). 
 
 13R was prepared using the same procedure as the S 
diastereomer to yield the product as a white powder in 
quantitative yield (92 mg). TLC Rf : 0.17 (DCM/MeOH 
97.5:2.5). 1H NMR (400 MHz; CDCl3): δ 1.19-1.30 (bm, 3H), 1.41 (dd, 3H, J = 
47.6, 5.6 Hz), 2.28 (m, 1H), 2.49 (m, 1H), 2.96 (q, 2H), 3.59-3.78 (bm, 2H), 4.42 
(m, 1H), 4.86 (s, 1H), 4.87 (s, 1H), 5.14-5.36 (dq, 1H, J = 82.8, 5.6 Hz), 6.59 (d, 
1H), 7.50 (dt, 2H), 7.59 (t, 1H), 7.97 (d, 2H), 8.73 (s, 1H). ESI-MS (pos.): 
426.1772 [M+H]+ (HSMS calc. 426.1777). 
 
Compound 14S and 14R 
N-Benzoyl-3’-(2-Cyanoethyl N,N-diisopropyl phosphorodiamidite)-5’-(1-
ethoxyethyl)-8,5’(S)-cyclo-2’-deoxyadenosine (14S) and N-Benzoyl-3’-(2-
Cyanoethyl N,N-diisopropyl phosphorodiamidite) -5’-(1-ethoxyethyl)-8,5’(R)-
cyclo-2’-deoxyadenosine (14R) 
 Compound 13S (66.0 mg, 0.155 mmol) was dissolved 
in acetonitrile (6.2 mL).  1H-tetrazole in acetonitrile (0.45 M 
solution in MeCN, 0.21 mL) was added followed by 2-
Cyanoethyl N,N,N',N'-tetraisopropyl phosphorodiamidite (61.0 μL, 0.186 
mmol) and the mixture was stirred overnight at ambient temperature. The 
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reaction was quenched with 5% trietheylamine in methanol and the solvents 
were removed under vacuum.  The residue was dissolved in DCM and washed 
with saturated sodium bicarbonate three times and once with brine. The 
organic layer was dried over sodium sulfate. After removing the sodium 
sulfate, hexanes were added to effect precipitation. The precipitate was 
collected by filtration and washed with hexanes several times to yield 14S as 
a white powder (60 mg, 60%). TLC Rf : 0.39 (DCM/MeOH 95:5). 31P NMR (162 
MHz; CDCl3): δ 146.7, 146.8, 147.0, 147.2. ESI-MS (pos.): 648.2671 [M+Na]+ 
(HSMS calc. 648.2675).  
 
 Compound 14R was obtained by a similar procedure 
as 14S to yield a white powder (22 mg, 50%). TLC Rf : 0.42 
(DCM/MeOH 95:5). 31P NMR (162 MHz; CDCl3): δ 147.4, 
147.6, 147.7, 147.9. ESI-MS (pos.): 648.2665 [M+Na]+ (HSMS calc. 648.2675). 
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2.7. Spectral and Crystal Data 
 
 
 
 
Figure 2.5. Crystal Structure of compound 12R used to confirm the 
stereochemistry of the cyclo-2’-deoxyadenosine diastereomers.  
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Figure 2.6. Thermal ellipsoid plot of 12R. 
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Table 2.4.  Crystal data and structure refinement for sad. 
Identification code  C26H35N5O4Si 
Empirical formula  C26 H35 N5 O4 Si 
Formula weight  509.68 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 13.7148(19) Å α= 90°. 
 b = 12.3887(17) Å β= 92.012(2)°. 
 c = 15.352(2) Å γ = 90°. 
Volume 2606.8(6) Å3 
Z 4 
Density (calculated) 1.299 Mg/m3 
Absorption coefficient 0.132 mm-1 
F(000) 1088 
Crystal size 0.18 x 0.07 x 0.03 mm3 
Theta range for data collection 2.22 to 28.35°. 
Index ranges -18<=h<=17, -16<=k<=16, -20<=l<=20 
Reflections collected 14888 
Independent reflections 6260 [R(int) = 0.0301] 
Completeness to theta = 28.35° 98.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9961 and 0.9767 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6260 / 36 / 431 
Goodness-of-fit on F2 1.051 
Final R indices [I>2sigma(I)] R1 = 0.0406, wR2 = 0.0959 
R indices (all data) R1 = 0.0477, wR2 = 0.1015 
Absolute structure parameter 0.01(9) 
Extinction coefficient na 
Largest diff. peak and hole 0.417 and -0.170 e.Å-3 
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Table 2.5.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for sad.  U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Si(1) 8095(1) -633(1) 1410(1) 18(1) 
O(1) 8221(1) -764(1) 2481(1) 22(1) 
O(2) 8596(1) -384(1) 4455(1) 17(1) 
O(3) 8622(1) 1962(1) 4630(1) 24(1) 
O(4) 3926(1) 1782(1) 7592(1) 38(1) 
N(1) 7084(1) -40(1) 5019(1) 16(1) 
N(2) 6086(1) -983(1) 6055(1) 19(1) 
N(3) 5028(1) 225(1) 6806(1) 23(1) 
N(4) 6529(1) 1651(1) 5210(1) 18(1) 
N(5) 4992(1) 2108(1) 6520(1) 20(1) 
C(1) 7658(1) -291(2) 3138(1) 20(1) 
C(2) 7268(1) -1180(2) 3734(1) 20(1) 
C(3) 7691(1) -871(1) 4623(1) 17(1) 
C(4) 6389(1) -115(1) 5633(1) 16(1) 
C(5) 5414(1) -740(2) 6627(1) 23(1) 
C(6) 5349(1) 1080(2) 6370(1) 18(1) 
C(7) 6057(1) 940(1) 5748(1) 18(1) 
C(8) 7132(1) 1033(1) 4791(1) 17(1) 
C(9) 7892(1) 1370(2) 4156(1) 19(1) 
C(10) 8343(1) 360(2) 3757(1) 19(1) 
C(11) 8728(1) 631(2) 1051(1) 22(1) 
C(12) 9833(2) 589(2) 1214(2) 31(1) 
C(13) 8312(2) 1640(2) 1475(2) 29(1) 
C(14) 8764(2) -1848(2) 1015(1) 22(1) 
C(15) 8675(2) -1981(2) 20(1) 31(1) 
C(16) 8503(2) -2892(2) 1471(1) 29(1) 
C(17) 6758(1) -538(2) 1097(1) 25(1) 
C(18) 6566(2) -216(2) 138(2) 36(1) 
C(19) 6177(2) -1545(2) 1316(2) 40(1) 
C(20) 4277(1) 2410(2) 7088(1) 20(1) 
C(21) 3953(1) 3564(2) 7037(1) 19(1) 
C(22) 3258(1) 3875(2) 7638(1) 22(1) 
C(23) 2899(1) 4915(2) 7632(1) 25(1) 
C(24) 3223(1) 5658(2) 7036(1) 24(1) 
C(25) 3908(1) 5363(2) 6439(1) 23(1) 
C(26) 4266(1) 4313(2) 6439(1) 20(1) 
________________________________________________________________________________
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Table 2.6.   Bond lengths [Å] and angles [°] for sad. 
_____________________________________________________ 
Si(1)-O(1)  1.6547(13) 
Si(1)-C(14)  1.874(2) 
Si(1)-C(11)  1.883(2) 
Si(1)-C(17)  1.8831(19) 
O(1)-C(1)  1.418(2) 
O(2)-C(3)  1.411(2) 
O(2)-C(10)  1.447(2) 
O(3)-C(9)  1.421(2) 
O(3)-H(3O)  0.859(16) 
O(4)-C(20)  1.210(2) 
N(1)-C(4)  1.366(2) 
N(1)-C(8)  1.377(2) 
N(1)-C(3)  1.469(2) 
N(2)-C(5)  1.330(2) 
N(2)-C(4)  1.331(2) 
N(3)-C(6)  1.336(2) 
N(3)-C(5)  1.340(3) 
N(4)-C(8)  1.311(2) 
N(4)-C(7)  1.384(2) 
N(5)-C(20)  1.386(2) 
N(5)-C(6)  1.386(2) 
N(5)-H(5N)  0.862(16) 
C(1)-C(10)  1.539(3) 
C(1)-C(2)  1.539(3) 
C(1)-H(1)  1.000(15) 
C(2)-C(3)  1.513(2) 
C(2)-H(2A)  0.983(15) 
C(2)-H(2B)  0.996(16) 
C(3)-H(3)  0.978(15) 
C(4)-C(7)  1.397(2) 
C(5)-H(5)  0.941(16) 
C(6)-C(7)  1.397(3) 
C(8)-C(9)  1.510(2) 
C(9)-C(10)  1.534(3) 
C(9)-H(9)  0.988(15) 
C(10)-H(10)  0.991(15) 
C(11)-C(12)  1.528(3) 
C(11)-C(13)  1.529(3) 
C(11)-H(11)  1.002(15) 
C(12)-H(12A)  0.985(17) 
C(12)-H(12B)  0.975(17) 
C(12)-H(12C)  0.989(17) 
C(13)-H(13A)  1.010(17) 
C(13)-H(13B)  1.004(16) 
C(13)-H(13C)  0.999(17) 
C(14)-C(16)  1.521(3) 
C(14)-C(15)  1.537(3) 
C(14)-H(14)  0.999(15) 
C(15)-H(15A)  0.987(17) 
C(15)-H(15B)  0.982(17) 
C(15)-H(15C)  0.974(17) 
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C(16)-H(16A)  0.984(17) 
C(16)-H(16B)  1.008(17) 
C(16)-H(16C)  1.001(16) 
C(17)-C(19)  1.524(3) 
C(17)-C(18)  1.540(3) 
C(17)-H(17)  0.998(16) 
C(18)-H(18A)  0.992(17) 
C(18)-H(18B)  1.001(18) 
C(18)-H(18C)  0.987(17) 
C(19)-H(19A)  0.982(17) 
C(19)-H(19B)  0.999(17) 
C(19)-H(19C)  0.971(18) 
C(20)-C(21)  1.498(3) 
C(21)-C(26)  1.385(3) 
C(21)-C(22)  1.403(3) 
C(22)-C(23)  1.379(3) 
C(22)-H(22)  0.944(16) 
C(23)-C(24)  1.383(3) 
C(23)-H(23)  0.973(16) 
C(24)-C(25)  1.384(3) 
C(24)-H(24)  0.931(16) 
C(25)-C(26)  1.390(3) 
C(25)-H(25)  0.953(16) 
C(26)-H(26)  0.933(15) 
 
O(1)-Si(1)-C(14) 102.01(8) 
O(1)-Si(1)-C(11) 109.87(8) 
C(14)-Si(1)-C(11) 109.70(8) 
O(1)-Si(1)-C(17) 109.04(8) 
C(14)-Si(1)-C(17) 116.80(9) 
C(11)-Si(1)-C(17) 109.13(9) 
C(1)-O(1)-Si(1) 128.76(11) 
C(3)-O(2)-C(10) 102.58(12) 
C(9)-O(3)-H(3O) 110.0(17) 
C(4)-N(1)-C(8) 106.34(14) 
C(4)-N(1)-C(3) 131.09(15) 
C(8)-N(1)-C(3) 122.56(14) 
C(5)-N(2)-C(4) 111.96(16) 
C(6)-N(3)-C(5) 117.75(16) 
C(8)-N(4)-C(7) 103.74(15) 
C(20)-N(5)-C(6) 127.89(16) 
C(20)-N(5)-H(5N) 120.2(16) 
C(6)-N(5)-H(5N) 111.9(16) 
O(1)-C(1)-C(10) 108.68(14) 
O(1)-C(1)-C(2) 109.63(15) 
C(10)-C(1)-C(2) 103.00(14) 
O(1)-C(1)-H(1) 114.6(13) 
C(10)-C(1)-H(1) 108.6(13) 
C(2)-C(1)-H(1) 111.6(13) 
C(3)-C(2)-C(1) 103.01(15) 
C(3)-C(2)-H(2A) 114.0(12) 
C(1)-C(2)-H(2A) 116.7(13) 
C(3)-C(2)-H(2B) 108.1(13) 
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C(1)-C(2)-H(2B) 109.8(13) 
H(2A)-C(2)-H(2B) 105.1(18) 
O(2)-C(3)-N(1) 106.91(13) 
O(2)-C(3)-C(2) 104.76(13) 
N(1)-C(3)-C(2) 110.22(14) 
O(2)-C(3)-H(3) 106.6(12) 
N(1)-C(3)-H(3) 107.4(12) 
C(2)-C(3)-H(3) 120.1(13) 
N(2)-C(4)-N(1) 128.90(16) 
N(2)-C(4)-C(7) 125.86(16) 
N(1)-C(4)-C(7) 105.23(15) 
N(2)-C(5)-N(3) 128.75(19) 
N(2)-C(5)-H(5) 116.5(14) 
N(3)-C(5)-H(5) 114.6(14) 
N(3)-C(6)-N(5) 121.41(16) 
N(3)-C(6)-C(7) 119.52(16) 
N(5)-C(6)-C(7) 119.07(17) 
N(4)-C(7)-C(4) 110.98(15) 
N(4)-C(7)-C(6) 132.85(17) 
C(4)-C(7)-C(6) 116.16(16) 
N(4)-C(8)-N(1) 113.70(15) 
N(4)-C(8)-C(9) 128.02(16) 
N(1)-C(8)-C(9) 118.14(15) 
O(3)-C(9)-C(8) 107.60(14) 
O(3)-C(9)-C(10) 109.80(15) 
C(8)-C(9)-C(10) 109.21(15) 
O(3)-C(9)-H(9) 114.1(13) 
C(8)-C(9)-H(9) 111.7(12) 
C(10)-C(9)-H(9) 104.3(13) 
O(2)-C(10)-C(9) 108.23(13) 
O(2)-C(10)-C(1) 104.43(14) 
C(9)-C(10)-C(1) 115.37(15) 
O(2)-C(10)-H(10) 108.1(13) 
C(9)-C(10)-H(10) 110.2(14) 
C(1)-C(10)-H(10) 110.1(13) 
C(12)-C(11)-C(13) 109.95(17) 
C(12)-C(11)-Si(1) 112.83(14) 
C(13)-C(11)-Si(1) 111.88(14) 
C(12)-C(11)-H(11) 107.4(13) 
C(13)-C(11)-H(11) 109.0(14) 
Si(1)-C(11)-H(11) 105.5(14) 
C(11)-C(12)-H(12A) 112.4(16) 
C(11)-C(12)-H(12B) 109.5(17) 
H(12A)-C(12)-H(12B) 108(2) 
C(11)-C(12)-H(12C) 110.1(15) 
H(12A)-C(12)-H(12C) 108(2) 
H(12B)-C(12)-H(12C) 109(2) 
C(11)-C(13)-H(13A) 108.0(15) 
C(11)-C(13)-H(13B) 111.5(16) 
H(13A)-C(13)-H(13B) 111(2) 
C(11)-C(13)-H(13C) 111.5(17) 
H(13A)-C(13)-H(13C) 109(2) 
H(13B)-C(13)-H(13C) 106(2) 
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C(16)-C(14)-C(15) 110.76(17) 
C(16)-C(14)-Si(1) 114.08(14) 
C(15)-C(14)-Si(1) 112.68(15) 
C(16)-C(14)-H(14) 104.5(13) 
C(15)-C(14)-H(14) 109.1(12) 
Si(1)-C(14)-H(14) 105.1(13) 
C(14)-C(15)-H(15A) 111.4(16) 
C(14)-C(15)-H(15B) 113.7(16) 
H(15A)-C(15)-H(15B) 107(2) 
C(14)-C(15)-H(15C) 111.6(16) 
H(15A)-C(15)-H(15C) 111(2) 
H(15B)-C(15)-H(15C) 102(2) 
C(14)-C(16)-H(16A) 112.5(16) 
C(14)-C(16)-H(16B) 109.4(16) 
H(16A)-C(16)-H(16B) 111(2) 
C(14)-C(16)-H(16C) 110.1(16) 
H(16A)-C(16)-H(16C) 105(2) 
H(16B)-C(16)-H(16C) 109(2) 
C(19)-C(17)-C(18) 110.46(18) 
C(19)-C(17)-Si(1) 113.83(15) 
C(18)-C(17)-Si(1) 113.12(14) 
C(19)-C(17)-H(17) 104.8(14) 
C(18)-C(17)-H(17) 103.4(13) 
Si(1)-C(17)-H(17) 110.4(14) 
C(17)-C(18)-H(18A) 108.2(17) 
C(17)-C(18)-H(18B) 115.3(18) 
H(18A)-C(18)-H(18B) 107(2) 
C(17)-C(18)-H(18C) 113.7(17) 
H(18A)-C(18)-H(18C) 109(2) 
H(18B)-C(18)-H(18C) 103(2) 
C(17)-C(19)-H(19A) 113.1(19) 
C(17)-C(19)-H(19B) 116.1(18) 
H(19A)-C(19)-H(19B) 104(2) 
C(17)-C(19)-H(19C) 111.0(19) 
H(19A)-C(19)-H(19C) 106(3) 
H(19B)-C(19)-H(19C) 106(3) 
O(4)-C(20)-N(5) 122.31(17) 
O(4)-C(20)-C(21) 121.57(16) 
N(5)-C(20)-C(21) 116.12(16) 
C(26)-C(21)-C(22) 119.11(17) 
C(26)-C(21)-C(20) 125.11(16) 
C(22)-C(21)-C(20) 115.75(17) 
C(23)-C(22)-C(21) 120.16(18) 
C(23)-C(22)-H(22) 121.1(14) 
C(21)-C(22)-H(22) 118.7(14) 
C(22)-C(23)-C(24) 120.21(18) 
C(22)-C(23)-H(23) 119.1(15) 
C(24)-C(23)-H(23) 120.7(15) 
C(23)-C(24)-C(25) 120.27(18) 
C(23)-C(24)-H(24) 116.4(15) 
C(25)-C(24)-H(24) 123.4(15) 
C(24)-C(25)-C(26) 119.69(18) 
C(24)-C(25)-H(25) 120.2(14) 
62 
 
C(26)-C(25)-H(25) 120.0(14) 
C(21)-C(26)-C(25) 120.55(16) 
C(21)-C(26)-H(26) 121.6(15) 
C(25)-C(26)-H(26) 117.8(15) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 2.7.   Anisotropic displacement parameters (Å2x 103)for sad.  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... 
+ 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Si(1) 21(1)  17(1) 16(1)  1(1) 3(1)  1(1) 
O(1) 28(1)  22(1) 16(1)  0(1) 5(1)  9(1) 
O(2) 18(1)  15(1) 19(1)  4(1) 4(1)  1(1) 
O(3) 28(1)  15(1) 27(1)  3(1) 1(1)  -6(1) 
O(4) 41(1)  19(1) 57(1)  3(1) 30(1)  5(1) 
N(1) 19(1)  12(1) 18(1)  -1(1) 4(1)  0(1) 
N(2) 20(1)  14(1) 24(1)  -1(1) 5(1)  0(1) 
N(3) 22(1)  18(1) 31(1)  -2(1) 8(1)  0(1) 
N(4) 21(1)  12(1) 21(1)  -2(1) 2(1)  1(1) 
N(5) 20(1)  15(1) 24(1)  -2(1) 6(1)  1(1) 
C(1) 23(1)  18(1) 18(1)  -1(1) 4(1)  5(1) 
C(2) 21(1)  18(1) 21(1)  -2(1) 4(1)  1(1) 
C(3) 18(1)  13(1) 19(1)  1(1) 6(1)  3(1) 
C(4) 15(1)  15(1) 18(1)  -4(1) 1(1)  2(1) 
C(5) 23(1)  16(1) 31(1)  0(1) 8(1)  -2(1) 
C(6) 16(1)  16(1) 24(1)  -4(1) 2(1)  1(1) 
C(7) 17(1)  14(1) 21(1)  -2(1) 0(1)  0(1) 
C(8) 20(1)  12(1) 18(1)  -1(1) 0(1)  0(1) 
C(9) 21(1)  16(1) 19(1)  3(1) 2(1)  -1(1) 
C(10) 20(1)  17(1) 19(1)  5(1) 6(1)  1(1) 
C(11) 25(1)  20(1) 21(1)  1(1) 2(1)  -1(1) 
C(12) 25(1)  27(1) 41(1)  -1(1) 5(1)  -4(1) 
C(13) 30(1)  19(1) 39(1)  3(1) 6(1)  1(1) 
C(14) 25(1)  21(1) 21(1)  -4(1) 7(1)  0(1) 
C(15) 43(1)  30(1) 22(1)  -4(1) 8(1)  -6(1) 
C(16) 35(1)  21(1) 30(1)  -2(1) 4(1)  3(1) 
C(17) 23(1)  24(1) 28(1)  4(1) 0(1)  -2(1) 
C(18) 30(1)  42(1) 36(1)  10(1) -8(1)  -3(1) 
C(19) 29(1)  42(2) 50(2)  12(1) -2(1)  -10(1) 
C(20) 16(1)  15(1) 28(1)  -5(1) 5(1)  -1(1) 
C(21) 16(1)  18(1) 24(1)  -3(1) 0(1)  0(1) 
C(22) 22(1)  20(1) 26(1)  -2(1) 5(1)  0(1) 
C(23) 25(1)  22(1) 30(1)  -4(1) 6(1)  5(1) 
C(24) 24(1)  19(1) 29(1)  -2(1) -3(1)  5(1) 
C(25) 25(1)  20(1) 23(1)  2(1) -3(1)  1(1) 
C(26) 19(1)  20(1) 22(1)  -4(1) 2(1)  1(1) 
______________________________________________________________________________
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Table 2.8.   Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for sad. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(3O) 8752(18) 2549(16) 4359(16) 35 
H(5N) 5251(15) 2582(17) 6189(14) 24 
H(1) 7124(14) 196(17) 2916(14) 24 
H(2A) 6559(11) -1291(19) 3717(13) 24 
H(2B) 7549(15) -1890(14) 3572(14) 24 
H(3) 7822(15) -1426(15) 5064(12) 20 
H(5) 5210(16) -1306(16) 6986(13) 28 
H(9) 7598(14) 1762(18) 3652(12) 22 
H(10) 8948(13) 551(19) 3459(13) 23 
H(11) 8602(16) 670(20) 405(10) 27 
H(12A) 10156(19) 1265(17) 1049(17) 47 
H(12B) 10100(20) 3(19) 875(17) 47 
H(12C) 9988(18) 460(20) 1839(11) 47 
H(13A) 8614(18) 2292(17) 1196(16) 44 
H(13B) 8434(19) 1640(20) 2124(11) 44 
H(13C) 7588(13) 1680(20) 1383(17) 44 
H(14) 9463(12) -1720(19) 1191(14) 27 
H(15A) 9098(17) -2568(18) -182(18) 47 
H(15B) 8852(19) -1330(18) -303(16) 47 
H(15C) 8000(13) -2090(30) -178(17) 47 
H(16A) 8969(17) -3477(19) 1362(17) 43 
H(16B) 7819(14) -3110(20) 1285(16) 43 
H(16C) 8537(19) -2790(20) 2118(11) 43 
H(17) 6445(16) 56(16) 1426(14) 30 
H(18A) 5853(13) -120(20) 39(18) 54 
H(18B) 6784(18) -750(20) -301(16) 54 
H(18C) 6910(19) 446(19) -33(18) 54 
H(19A) 5471(13) -1450(30) 1216(19) 61 
H(19B) 6250(20) -1800(20) 1931(13) 61 
H(19C) 6360(20) -2150(20) 955(18) 61 
H(22) 3047(16) 3360(16) 8044(13) 27 
H(23) 2418(15) 5120(20) 8054(14) 30 
H(24) 2959(16) 6349(15) 7067(15) 29 
H(25) 4117(16) 5869(17) 6017(13) 27 
H(26) 4737(13) 4141(19) 6036(12) 24 
________________________________________________________________________________
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Table 2.9.  Torsion angles [°] for sad. 
________________________________________________________________ 
C(14)-Si(1)-O(1)-C(1) -159.98(16) 
C(11)-Si(1)-O(1)-C(1) 83.71(17) 
C(17)-Si(1)-O(1)-C(1) -35.85(18) 
Si(1)-O(1)-C(1)-C(10) -122.85(14) 
Si(1)-O(1)-C(1)-C(2) 125.27(15) 
O(1)-C(1)-C(2)-C(3) 120.80(15) 
C(10)-C(1)-C(2)-C(3) 5.25(17) 
C(10)-O(2)-C(3)-N(1) -69.48(15) 
C(10)-O(2)-C(3)-C(2) 47.50(16) 
C(4)-N(1)-C(3)-O(2) -146.68(17) 
C(8)-N(1)-C(3)-O(2) 34.3(2) 
C(4)-N(1)-C(3)-C(2) 100.0(2) 
C(8)-N(1)-C(3)-C(2) -79.00(19) 
C(1)-C(2)-C(3)-O(2) -32.18(17) 
C(1)-C(2)-C(3)-N(1) 82.51(16) 
C(5)-N(2)-C(4)-N(1) 178.14(17) 
C(5)-N(2)-C(4)-C(7) -0.6(3) 
C(8)-N(1)-C(4)-N(2) -179.45(17) 
C(3)-N(1)-C(4)-N(2) 1.4(3) 
C(8)-N(1)-C(4)-C(7) -0.48(18) 
C(3)-N(1)-C(4)-C(7) -179.61(16) 
C(4)-N(2)-C(5)-N(3) 0.6(3) 
C(6)-N(3)-C(5)-N(2) -0.7(3) 
C(5)-N(3)-C(6)-N(5) -179.64(17) 
C(5)-N(3)-C(6)-C(7) 0.6(3) 
C(20)-N(5)-C(6)-N(3) -1.6(3) 
C(20)-N(5)-C(6)-C(7) 178.17(17) 
C(8)-N(4)-C(7)-C(4) -0.48(19) 
C(8)-N(4)-C(7)-C(6) 178.27(19) 
N(2)-C(4)-C(7)-N(4) 179.62(16) 
N(1)-C(4)-C(7)-N(4) 0.62(19) 
N(2)-C(4)-C(7)-C(6) 0.6(3) 
N(1)-C(4)-C(7)-C(6) -178.36(15) 
N(3)-C(6)-C(7)-N(4) -179.29(18) 
N(5)-C(6)-C(7)-N(4) 0.9(3) 
N(3)-C(6)-C(7)-C(4) -0.6(2) 
N(5)-C(6)-C(7)-C(4) 179.64(15) 
C(7)-N(4)-C(8)-N(1) 0.17(19) 
C(7)-N(4)-C(8)-C(9) -175.49(17) 
C(4)-N(1)-C(8)-N(4) 0.2(2) 
C(3)-N(1)-C(8)-N(4) 179.43(15) 
C(4)-N(1)-C(8)-C(9) 176.33(15) 
C(3)-N(1)-C(8)-C(9) -4.5(2) 
N(4)-C(8)-C(9)-O(3) 67.1(2) 
N(1)-C(8)-C(9)-O(3) -108.35(17) 
N(4)-C(8)-C(9)-C(10) -173.73(16) 
N(1)-C(8)-C(9)-C(10) 10.8(2) 
C(3)-O(2)-C(10)-C(9) 79.96(16) 
C(3)-O(2)-C(10)-C(1) -43.44(15) 
O(3)-C(9)-C(10)-O(2) 70.15(17) 
C(8)-C(9)-C(10)-O(2) -47.62(18) 
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O(3)-C(9)-C(10)-C(1) -173.34(14) 
C(8)-C(9)-C(10)-C(1) 68.90(19) 
O(1)-C(1)-C(10)-O(2) -93.88(16) 
C(2)-C(1)-C(10)-O(2) 22.35(17) 
O(1)-C(1)-C(10)-C(9) 147.47(15) 
C(2)-C(1)-C(10)-C(9) -96.29(17) 
O(1)-Si(1)-C(11)-C(12) 65.01(16) 
C(14)-Si(1)-C(11)-C(12) -46.35(16) 
C(17)-Si(1)-C(11)-C(12) -175.48(14) 
O(1)-Si(1)-C(11)-C(13) -59.59(16) 
C(14)-Si(1)-C(11)-C(13) -170.96(15) 
C(17)-Si(1)-C(11)-C(13) 59.91(16) 
O(1)-Si(1)-C(14)-C(16) 47.07(16) 
C(11)-Si(1)-C(14)-C(16) 163.51(15) 
C(17)-Si(1)-C(14)-C(16) -71.68(17) 
O(1)-Si(1)-C(14)-C(15) 174.49(14) 
C(11)-Si(1)-C(14)-C(15) -69.08(16) 
C(17)-Si(1)-C(14)-C(15) 55.73(17) 
O(1)-Si(1)-C(17)-C(19) -62.88(18) 
C(14)-Si(1)-C(17)-C(19) 52.02(19) 
C(11)-Si(1)-C(17)-C(19) 177.11(16) 
O(1)-Si(1)-C(17)-C(18) 169.96(16) 
C(14)-Si(1)-C(17)-C(18) -75.15(19) 
C(11)-Si(1)-C(17)-C(18) 49.95(19) 
C(6)-N(5)-C(20)-O(4) 6.4(3) 
C(6)-N(5)-C(20)-C(21) -173.00(16) 
O(4)-C(20)-C(21)-C(26) -175.15(19) 
N(5)-C(20)-C(21)-C(26) 4.3(3) 
O(4)-C(20)-C(21)-C(22) 3.1(3) 
N(5)-C(20)-C(21)-C(22) -177.50(16) 
C(26)-C(21)-C(22)-C(23) -0.3(3) 
C(20)-C(21)-C(22)-C(23) -178.67(17) 
C(21)-C(22)-C(23)-C(24) -0.2(3) 
C(22)-C(23)-C(24)-C(25) 0.2(3) 
C(23)-C(24)-C(25)-C(26) 0.3(3) 
C(22)-C(21)-C(26)-C(25) 0.8(3) 
C(20)-C(21)-C(26)-C(25) 179.00(17) 
C(24)-C(25)-C(26)-C(21) -0.8(3) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 2.10.  Hydrogen bonds for sad [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 O(3)-H(3O)...N(2)#1 0.859(16) 1.942(17) 2.788(2) 168(3) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y+1/2,-z+1      
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Figure 2.7. HPLC traces for Table 2.3. a) Control sequence. b) Modified 
sequence. 
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Figure 2.8. TM isotherm for entry 1 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. TM isotherm for entry 2 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
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Figure 2.10. TM isotherm for entry 3 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. TM isotherm for entry 4 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
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Figure 2.12. TM isotherm for entry 5 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. TM isotherm for entry 6 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
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Figure 2.14. TM isotherm for entry 7 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. TM isotherm for entry 8 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
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Figure 2.16. TM isotherm for entry 9 in Table 2.1. DNA concentration: 0.5 μM 
for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17. TM isotherm for entry 10 in Table 2.1. DNA concentration: 0.5 
μM for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM 
NaCl. 
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Figure 2.18. TM isotherm for entry 11 in Table 2.1. DNA concentration: 0.5 
μM for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 mM 
NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19. TM isotherm for entry 15 in Table 2.1. RNA, DNA  concentration: 
0.5 μM for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 
mM NaCl. 
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Figure 2.20. TM isotherm for entry 16 in Table 2.1. RNA, DNA concentration: 
0.5 μM for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 
mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21. TM isotherm for entry 17 in Table 2.1. RNA, DNA concentration: 
0.5 μM for each sequence. Buffer condition: 20 mM phosphate pH 7.0, 100 
mM NaCl. 
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Figure 2.22. CD Spectra for entry 1 to entry 4 in Table 2.1. DNA 
concentration: 4.0 μM for each sequence. Buffer condition: 20 mM phosphate 
pH 7.0, 100 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23. CD Spectra for entry 15 to entry 17 in Table 2.1. RNA and DNA 
concentration: 4.0 μM for each sequence. Buffer condition: 20 mM phosphate 
pH 7.0, 100 mM NaCl. 
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Chapter 3 
Synthesis and Characterization of Ring-Expanded Cyclo-
2’-Deoxynucleic Acids 
 
 
 
 
 
 
 
 
 
 
102 
 
3. Synthesis and Characterization of Ring-Expanded Cyclo-2’-
Deoxynucleic Acids 
 
3.1. Introduction 
     Chemical modification of nucleic acids has been drawing a lot of 
attention for many decades due to the potential for treatment of serious 
diseases such as viral infections, cancer and genetic disorders. The modified 
nucleic acid analogues are designed with the goal of effectively and 
selectively targeting single stranded DNA and RNA. 1-5 
DNA composed of the nucleosides containing rigidified sugars (e.g. 
Locked Nucleic Acids6,7) is generally more stable than the corresponding 
native sequences.8,9  This effect likely reflects a more favorable entropic effect 
in the energetics of helix formation since the rigidified sugars have some 
degree of preorganization toward the conformation present in the DNA 
duplex. Previously we synthesized 8,5’-cyclo-2’-deoxyadenosine and 6,5’-cyclo-
2’-deoxyuridine (1S, 1R and 2S, 2R in Figure 3.1).10 These cyclo-nucleosides 
can be formed through oxidative damage to DNA. It is known that cyclo-
nucleosides inhibit binding of proteins such as the TATA binding protein.11 
These rigidified cyclo-nucleosides were incorporated into DNA oligomers to 
study whether such species inhibited protein binding by deforming the 
backbone, or by enhanced binding to the complimentary strand. Thermal 
melting studies showed that the sequences with these rigid nucleosides did  
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Figure 3.1. The first generation cyclo-deoxynucleosides: 8,5’-cyclo-2’-
deoxyadenosines (1S, 1R) and 6,5’-cyclo-2’-deoxyuridines (2S, 2R); the novel 
ring-expanded-8,5’-cyclo-deoxynucleosides (3S and 3R). 
 
 
 
 
 
 
 
Figure 3.2. The crystal structures of 1R, with protecting groups hidden, and 
2S overlayed with 2’-dA and 2’-dU (green structures).10,12,13 The extra linkage 
pulls the base away from the hydrogen bonding center. 
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not form stable duplexes, likely the reasoning behind the reduced binding 
affinity of the TBP. 
The crystal structures of the cyclo-nucleosides (cyclo-dA and cyclo-dU) 
are one crucial piece of evidence to explain this phenomenon.10 The extra 
linkage between the sugar and base “locked” the modified nucleoside into a 
pre-organized structure and restricted the χ-angle into a fixed position as we 
designed, but it also “pulled” the base away from its natural position, causing 
duplex destabilization (Figure 3.2). 
Here we present the synthesis of a new class of cyclo-deoxynucleosides: 
the ring-expanded cyclo-deoxynucleosides. Our theory is that by introducing 
an extra methylene onto the cyclized linkage, we could “push” the base back 
towards its natural position. The linkage should also decrease entropic 
rotation around the glycosidic bond. The ribose version of the ring-expanded 
adenosine analogues has been synthesized before, but the chirality on the C5’ 
position has never been solved.14 In this chapter we not only successfully 
synthesized both diastereomers of ring-expanded cyclo-deoxyadenosine but 
clarified the stereochemistry. 
 
 
3.2. Synthesis of Ring-Expanded-8,5’-Cyclo-2’-Deoxyadenosine  
The goal of this study was to prepare both diastereomers of Ring-
Expanded-8,5’-Cyclo-2’-Deoxyadenosine based upon Cyclo-Deoxyadenosine. 
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Introducing an extra methylene group into the bridge between the sugar and 
the heterocycle of cyclo-dA would rigidify the nucleosides and “push” the 
nucleobase back to the helical center.   Model building studies suggested that 
the S- diastereomer would result in similar glycosidic bond angles and closer 
space orientation on the sugar and base to the dA observed in double-
stranded nucleic acids15 (Figure 3.3).  
 
 
 
 
 
 
Figure 3.3. Molecular modeling of 3S and dA (green structure).11 The extra 
methylene linkage restricts the base rotation against the glycosidic bond and 
allows the hydrogen binding sites to move closer to the helical center. 
 
 
The first synthetic strategy we envisioned was going through the 
rhodium-catalyzed dediazotization/rearrangement studied by Pellicciari and 
Nagao16,17. The ring-expanded cyclo-nucleosides could be formed by reducing 
the ring-expanded cyclized-ketone compound. The ketone compound was 
generated by rhodium-catalyzed rearrangement on an important 
intermediate (4) from the synthesis of cyclo-dA then followed with 
decarboxylation (Scheme 3.1).10,18 
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Scheme 3.1. Retro-synthesis of the ring-expanded 8,5’-cyclo-2’-deoxy-
adenosine by rhodium-catalyzed rearrangement. 
 
 
 
 
The synthesis started with compound 4 (ref. 10) that was treated with 
7N ammonium hydroxide in methanol to remove the N-benzoyl group, thus 
avoiding a side reaction in which the ethyl diazoacetate would react with the 
benzoylamide in the next step. Then ethyl diazoacetate was reacted with 
freshly made LDA (Lithium diisopropylamide) at -78 oC to generate the 
lithiated ethyl α-diazoacetate intermediate. This was added to compound 5 
which resulted in diastereomeric alcohols, compounds 6S and 6R which were 
characterized by proton NMR and high-resolution mass. Unfortunately, the 
rearrangement never succeeded, even when the amino group was re-
protected as an imino group prior to the rhodium-catalyzed reaction (Scheme 
3.2). 
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Scheme 3.2. Synthetic scheme following the rhodium-catalyzed 
rearrangement strategy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.3. Synthesis of the R and S diastereomers of ring expanded-8,5’-
cyclo-2’-deoxyadenosine. 
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 We therefore revised our strategy toward the 8,5’-cyclo-2’-
deoxyadenosine synthesis.10 The idea was to insert an iodomethylene group 
onto the 5’ carbon of the sugar, followed by a zinc mediated cyclization 
reaction to generate the ring-expanded nucleoside.  
The synthesis (Scheme 3.3) started with N-benzoylated 2’-
deoxyadenosine10 (compound 8) to perform a “transient protection”, 
protecting the 3’-OH with a silyl protecting group but leaving the 5’-OH free. 
Firstly we treated compound 8 with DMTrCl to selectively protect the 
primary 5’-OH with a bulky, acid labile group to get compound 9 with a very 
good yield. The trityl group could fall off during the silica gel 
chromatography, so the elution solvent had to contain 1% TEA. The next step 
was to protect the 3’-OH with the triisopropylsilyl (TIPS) protecting group. 
Then using the mild acid, p-toluenesulfonic acid, at low temperature we could 
remove the acid labile DMTr group from the 5’-O position while avoiding de-
purination to obtain compound 10. 
 
 
 
 
 
Scheme 3.4. Synthesis of compound 9 and compound 10. 
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 The next step was to attach the 6’ carbon on to the sugar. Compound 
10 was oxidized by the self-prepared Dess-Martin periodinane19 reagent to 
generate the 5’-aldehyde compound. This aldehyde compound did not have 
effective UV absorption, did not char well, and was found unstable under 
column purification conditions. We therefore performed the next Wittig 
reaction right after work-up to install the terminal olefin (compound 11) with 
a 59% yield in 2 steps. 
 
 
 
 
Scheme 3.5. Synthesis of compound 11. 
 
 Compound 11 was then treated with a catalytic amount of osmium 
tetroxide to oxidize the terminal alkene into the racemic dihydroxy compound 
(12). These racemic compounds were inseparable, but the two diastereomers 
could be separated by column chromatography in the next step after putting 
the p- tosyl group on the 6’-OH. It was very hard to avoid the di-tosylated 
side products during this tosylation reaction; the low temperature condition 
(4 oC) helped to suppress the formation of these side products to about 10%. 
The separation on a silica gel column was also a big challenge. We were able 
to efficiently separate them using 2% IPA in DCM as an elution solvent. At 
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this stage, we named these two diastereomers as 13H and 13L according to 
their movement on the TLC plate, Higher or Lower. 
 
 
 
 
Scheme 3.6. Synthesis of compound 12 and compound 13. 
 
 The next step was to convert the 6’-O –tosyl into a 6’-iodo group with 
very good yields for both diastereomers (compound 14H and 14L) using 
sodium iodide in acetone under reflux condition. The zinc-mediated 
cyclization was at first not performing well under the conditions used in the 
cyclo-dA synthesis.6 We therefore performed the sonication induced 
cyclization reaction followed by tetrachloro-benzoquinone to regenerate the 
aromaticity of the purine base and get compounds 15S and 15R. The chirality 
of the ring-expanded cyclo-dA could now be solved using 2D-NMR studies 
that will be discussed in section 3.3.  
 
 
 
 
Scheme 3.7. Synthesis of compound 14 and compound 15. 
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 The free ring-expanded cyclo-nucleosides (3S and 3R) were obtained 
from 15S  and 15R  using with tetra-n-butylammonium fluoride (TBAF) in  
tetrahydrofuran (THF)  to remove the triisopropylsily (TIPS) protecting group 
on the 3’-OH, followed by 7N ammonia in methanol to remove the benzoyl 
group on the 6-amino position. The final compounds (3S and 3R) were very 
polar, making it hard to purify them on a silica gel column, but they could be 
purified by HPLC using a reversed phase C18 column with water and 
acetonitrile as elution solvents. 
 
 
 
 
Scheme 3.8. Synthesis of compound 3. 
 
 
3.3. Characterization of the Chirality 
 Since we introduced an extra methylene group on to the bridge of  
nucleobase and 5’ carbon of  sugar, there was a new chiral center generated, 
the C5’. It was a great challenge to solve and characterize these two 
diastereomers. Due to the synthetic strategy, two diastereomers were 
generated after the osmium tetroxide reaction (compound 12). The two 
diastereomers could be separated after installing a tosyl group on the 6’-OH, 
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the stereochemistry remained unsolved until we generated and characterized 
the identity of cyclized compound 15. 
 From the top view of the ring-expanded cyclo-deoxyadenosines (Figure 
3.4) we knew that the distance between the 3’-H and 5’-H in S and R 
diastereomers would be very different, 3.75 Å in the S- diastereomer and 2.58 
Å in the R- diastereomer. This difference allowed us to perform 2D NMR 
experiments to clarify the stereochemistry of these two compounds. 
 
 
 
 
 
Figure 3.4. The top view for the two diastereomers of ring-expanded cyclo-
deoxyadenosines. The distance between the 3’-H and 5’-H in S and R 
diastereomers are very different, 3.749 Å in S- diastereomer and 2.578 Å in 
R- diastereomer. 
 
 
 Firstly, we performed two-dimensional homonuclear correlation 
spectroscopy (COSY) experiments to identify the position of the protons on 
the sugar for both diastereomers (the COSY spectra are in Chapter 3.7). We 
then carried out through-space nuclear Overhauser effect spectroscopy 
(NOESY) experiments. Results of the NOESY experiments are showed in 
figure 3.5. The 2D spectrum of the ring-expanded cyclo-dA synthesized from 
compound 13H (13H-->14H-->15H) showed that the 5’-H only had interaction 
113 
 
with the 4’-H, but no interaction with 3’-H (Figure 3.5.a.); in the NOESY 
spectrum of the ring-expanded cyclo-dA from compound 13L (13L-->14L--
>15L), 5’-H had interactions with both 4’-H and 3’-H (Figure 3.5.b.). 
The NOESY studies provided a clear indication that compound 15H is 
the S - diastereomer (15S), which has a longer distance between 3’ and 5’-H 
and no interaction between these protons in the spectrum. Compound 15L is 
the R - diastereomer (15R), and has a shorter distance between 3’ and 5’-H, 
showing an interaction in the NOESY experiment. The NOESY results also 
explained the movement of the compounds on the TLC plates. The 5’-OH of R 
- diastereomer is more accessible to the silica gel on the TLC which is more 
polar so moves slower (Rf: 0.24 ;DCM:MeOH = 91:9). It is the compound 15L 
(15R). Compound 15H (15S) is the S – diastereomer, which has a less 
accessible 5’-OH and is less polar than R - diastereomer, so it moves faster on 
the TLC (Rf: 0.27 ;DCM:MeOH = 91:9). 
 After the last two deprotection steps (Scheme 3.8), the final compounds 
(3S and 3R) were purified on HPLC using a reversed phase C18 column. The 
mobile phase solvent A was water and solvent was B acetonitrile. The 
running gradient started with 100% A, in 25 minutes changed to 80% A and 
20% B, then went back to 100% A in 2 minutes and the column was washed 
with pure solvent A (water) for 11 minutes to prepare it for the next run. The 
separation was very successful with the difference in retention time between 
two diastereomers being 3 minutes (Figure 3.6). 
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Figure 3.5. NOESY spectra for the S and R diastereomers of compound 16. a) 
the compound H, which is the S diastereomer, with a longer distance between 
3’ and 5’ protons; b)  the compound L, the R diastereomers, with a shorter 
distance between 3’ and 5’ protons. 
 
 
 
 
 
 
 
 
 
Figure 3.6. HPLC traces for compound 3S and 3R. a) the S - diastereomer, b) 
the R – diastereomer, c) co-injection of two diastereomers. The S - 
diastereomer has lower polarity than the R - diastereomer which has longer 
retention time on the C-18 reversed phase column. The co-injection is mixing 
two diastereomers after purification. 
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3.4. Conclusions 
 In this chapter, we presented an alternate design of the cyclo-
nucleosides: the ring-expanded cyclo-deoxyadenosine. The synthetic strategy 
successfully inserted an extra methylene group onto the bridge of the cyclo-
deoxyadenosine and obtained two novel ring-expanded cyclo-nucleosides. 
Using 2D NMR, we fully characterized these two diastereomers. The two free 
nucleosides of the ring-expanded cyclo-deoxyadenosine were purified by 
reversed phase HPLC and clarified the polarity difference correlated to the 
new generated chiral center on the C5’ position. In the future, there will be 
more experiments carried out with these novel rigidified cyclo-nucleosides. 
They could have better thermal stability than the first generation of cyclo-
nucleosides10 in the DNA strands, or have the potential to perform 
enzymatic/non-enzymatic polymerization. 
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3.5. Experimental 
 
Reagents were purchased from Sigma-Aldrich, Acros, Oakwood, Glen 
Research, Lancaster, MP Biomedical, Chem-Impex International, and Fisher. 
Flash column were performed using Dynamic Adsorbents silica gel (60 Å, 
particle size 32-63 m) and TLC monitoring with TLC Silica Gel with F-254 
Indicator (Dynamic Adsorbents). TLCs were visualized by 260nm UV light 
and stained by 10% sulfuric acid. Dry tetrahydrofuran (THF), diethyl ether 
(Et2O), N,N-dimethylformamide (DMF), pyridine (pyr), acetonitrile (MeCN), 
and dichloromethane (DCM) were obtained by passing commercially 
available pre-dried, oxygen-free formulations through activated alumina 
columns. Dry acetone was purchased from Sigma-Aldrich and used directly. 
NMR spectra were taken by Varian VNMRS400, VNMRS500, or INOVA 500 
instruments and calibrated using residual undeuterated solvent (CDCl3: δ H 
= 7.24 ppm, δ C = 77.00 ppm, D2O: δ H = 4.80 ppm, Pyridine-D5: δ C = 135.91 
ppm). Abbreviations of multiplicities were designated as follow: s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass 
spectra (HRMS) were recorded on a Waters LCT or JEOL AccuTOF mass 
spectrometer using ESI (electrospray ionization) or DART (direct analysis in 
real time).  HPLC was performed on Waters (Milford, MA) Delta 600 
controllers with a 2487 dual wavelength detector. 
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Compound 9 
  
Compound 8 (7.10 g, 20.0 mmol) and 4,4’-
dimethoxytritylchloride (8.13g, 24 mmol) were dissolved in 
dry pyridine (100 mL). Triethylamine (4.2 mL, 30 mmol) 
was added to the solution and the reaction mixture was kept under room 
temperature for 2 days. After the reaction had gone to completion 
(monitoring by TLC) water (30 mL) was added and the mixture was kept on 
ice for another 30 minutes. Solvents were removed under reduced pressure 
and the residue dissolved in dichloromethane and washed with water three 
times and once with brine.  The organic layer was dried over sodium sulfate 
and concentrated under vacuum.  The crude product was purified by flash 
chromatography (DCM:MeOH:Et3N = 97:2:1) to yield compound 9 as a white 
(12.0 g, 91%).  TLC Rf: 0.41 (DCM:MeOH = 97:3). 1H NMR (400 MHz, CDCl3): 
δ 2.46 (m, 1H), 2.76 (m, 1H), 3.31 (d, 2H), 3.68 (s, 6H), 4.11 (q, J = 4.1 Hz, 
1H), 4.61 (m, 1H), 6.41 (t, J = 6.4 Hz, 1H), 6.70 (dd, J = 8.8 Hz, 1.2 Hz, 4H), 
7.10-7.21 (m, 7H), 7.30 (dd, J = 6.8 Hz, 1.6 Hz, 2H), 7.42 (t, J = 7.6 Hz, 2H), 
7.51 (t, J = 7.2 Hz, 1H), 7.94 (dd, J = 7.2 Hz, 1.6 Hz, 2H), 8.09 (s, 1H), 8.63 (s, 
1H). 13C NMR (100MHz, CDCl3): δ 40.4, 55.2, 63.7, 71.9, 84.8, 86.4, 113.1, 
123.3, 126.9, 127.8, 127.9, 128.1, 128.8, 130.0, 132.7, 133.7, 135.6, 141.5, 
144.5, 149.4, 151.3, 152.4, 158.5, 164.8. . HRMS (pos.): 658.2648 [M+H]+ 
(HSMS calc. 658.2666). 
 
118 
 
 
Compound 10 
 
Compound 9 (5.60 g, 8.51 mmol), and imidazole (2.30 g, 
33.4 mmol) were dissolved in dry DMF (56 mL) and cooled to 
0 oC.  Triisopropylsilyl chloride (4.70 ml, 22.0 mmol) was 
added and the reaction was warmed to ambient temperature. After stirring 
for 1 day the reaction was quenched with water while on an ice bath. 200 mL 
of ethyl acetate was added into the mixture, which was extracted with brine 
solution three times and once with water. The organic layer was dried over 
sodium sulfate and concentrated under vacuum. The crude product was 
maintained under high vacuum overnight, then dissolved in dichloromethane 
(85 mL) and incubated on an ice bath. The methanol (20 mL) solution of p-
toluenesulfonic acid (0.69 g, 10.0 mmol) was added into the reaction mixture 
by drops. After stirring on the ice bath for half an hour, the reaction was 
quenched by saturated NaHCO3(aq) solution and extracted with water three 
times and once with brine.  The organic layer was dried over sodium sulfate 
and concentrated under vacuum.  The crude product was purified by flash 
chromatography (DCM:MeOH = 97:3) to yield compound 10 as a white solid 
(3.5 g, 74%, two steps). TLC Rf: 0.25 (DCM:MeOH = 97:3). 1H NMR (400 
MHz, CDCl3): δ 1.03-1.10 (m, 21H), 2.29 (dd, J = 12.8 Hz, 5.6 Hz, 1H), 3.01 
(m, 1H), 3.74 (d, J = 11.6 Hz, 1H), 3.93 (dd, J = 12.8 Hz, 1.6 Hz, 1H), 4.18 (s, 
1H), 4.75 (d, J = 4.8 Hz, 1H), 6.34 (dd, J = 9.6 Hz, 5.6 1H), 7.46 (t, J = 7.2 Hz, 
2H), 7.55 (t, J = 7.2 Hz, 1H), 7.98 (dd, J = 7.2 Hz,1.6 Hz, 2H), 8.08 (s, 1H), 
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8.70 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 11.9, 17.9, 41.7, 63.3, 74.1, 87.8, 
90.6, 124.5, 127.9, 128.8, 132.8, 133.5, 142.6, 150.2, 150.7, 152.0, 164.7. 
HRMS (pos.): 512.2675 [M+H]+ (HSMS calc. 512.2693). 
 
Compound 11 
 
Compound 10 (5.60 g, 10.9 mmol), Dess-Martin 
periodinane (6.95 g, 16.4 mmol) were dissolved in 
dichloromethane (110 mL). The reaction mixture was stirring 
under room temperature for one hour then quenched by Na2S2O3(aq) and 
NaHCO3(aq) then extrcteded with water three times and once with brine.  The 
organic layer was dried over sodium sulfate and concentrated under vacuum 
to get the crude aldehyde compound. The methyl triphenyl phosphonium 
bromide (14.29 g, 40.0 mmol) and potassium tert-butoxide were dissolved in 
THF (140 mL) and stirred under room temperature for an hour. The crude 
aldehyde from the Dess-Martin oxidation was dissolved in THF (40 mL) then 
added into the Wittig reagents mixture and stirred for overnight. The 
reaction was quenched by NH4Cl(aq) then extracted with water three times 
and once with brine.  The organic layer was dried over sodium sulfate and 
concentrated under vacuum to get the crude alkene compound. The crude 
product was purified by flash chromatography (Ethyl Acetate:Hexane = 
60:40) to yield compound 11 as a white solid (3.28 g, 59%).  TLC Rf: 0.38 
(DCM:MeOH = 97:3). 1H NMR (400 MHz, CDCl3): δ 1.00-1.14 (m, 21H), 2.53 
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(m, 1H), 2.87 (m, 1H), 4.48 (m, 1H), 4.60 (m, 1H), 5.24 (d, J = 10.0 Hz 1H), 
5.34 (d, J = 16.8 Hz 1H),   5.98 (m, 1H), 6.47 (t, J =  6.6Hz, 1H), 7.50 (t, J = 7.6 
Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 8.01 (d, J = 7.6 Hz, 2H), 8.15 (s, 1H), 8.78 (s, 
1H). 13C NMR (100 MHz, CDCl3): δ 12.0, 17.9, 40.2, 76.0, 84.9, 88.9, 118.0, 
123.7, 127.8, 128.7, 132.6, 133.6, 135.5, 141.7, 149.5, 151.5, 152.5, 164.7. 
HRMS (pos.): 508.2730 [M+H]+ (HSMS calc. 508.2744). 
 
Compound 12 
  
Compound 11 (4.08 g, 8.0 mmol), and N-methyl 
morpholine-N-oxide (2.49 g, 20.4 mmol) were dissolved in 
DCM (80 mL), then 1% osmium tetroxide aqueous solution (4.0 
mL, 0.16 mmol) was added into the solution. After stirring under room 
temperature for 3 hours, the reaction was quenched by Na2S2O3(aq) and 
extracted with water three times and once with brine. The organic layer was 
dried over sodium sulfate and concentrated under vacuum. The crude product 
was purified by flash chromatography (DCM:MeOH = 97:3) to yield the 
inseparable racemic compound 12 as a white solid (3.78 g, 87%).  TLC Rf: 0.42 
(DCM:MeOH = 97:3). HRMS (pos.): 542.2801 [M+H]+ (HSMS calc. 542.2793). 
 
Compound 13 
 
Compound 12 (3.48 g, 6.4 mmol), and 4-
dimethylaminopyridine (0.94 g, 7.7 mmol) were dissolved in 
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dry pyridine (30 mL) on ice bath, then 5 mL of p-toluenesulfonyl chloride 
(1.59 g, 8.3 mmol) pyridine solution was added into the mixture. The reaction 
was stirring in cold room (4 oC) for one day and checked by TLC. The reaction 
was quenched by water when it went completion, and extracted with water 
three times and once with brine. The organic layer was dried over sodium 
sulfate and concentrated under vacuum. The crude product was purified by 
flash chromatography (DCM:IPA = 98:2) to yield the compound 13H (1.51 g, 
34%) and 13L (1.836 g, 41%) as white solid. 
 
13H: TLC Rf: 0.47 (DCM:IPA = 97.5:2.5). 1H NMR (400 MHz, CDCl3): δ 0.97-
1.01 (m, 21H), 2.21 (dd, J = 12.8 Hz, 5.6 Hz, 1H), 2.32 (s, 3H), 2.85 (m, 1H), 
3.95 (m, 3H), 4.16 (s, 1H), 4.67 (d, J = 4.8Hz, 1H), 6.27 (m, 2H), 7.20 (d, J = 
8.0 Hz, 2H), 7.41 (t, J = 8.0 Hz, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.64 (d, J = 8.0 
Hz, 2H), 7.93 (d, J = 7.6 Hz, 2H), 8.04 (s, 1H), 8.50 (s, 1H), 9.26 (s, 1H). 13C 
NMR (100 MHz, CDCl3): δ 11.8, 17.8, 21.5, 41.2, 69.6, 69.7, 74.6, 87.7, 88.4, 
124.5, 127.7, 127.8, 128.7, 129.6, 132.6, 132.8, 133.2, 142.5, 144.8, 150.3, 
150.4, 151.6, 164.6. HRMS (pos.): 696.2873 [M+H]+ (HSMS calc. 696.2887). 
 
13L: TLC Rf: 0.38 (DCM:IPA = 97.5:2.5). 1H NMR (400 MHz, CDCl3): δ 1.01-
1.06 (m, 21H), 2.27 (dd, J = 13.2 Hz, 5.6 Hz, 1H), 2.39 (s, 3H), 3.01 (m, 1H), 
4.04-4.13 (m, 3H), 4.72 (d, J = 4.4Hz, 1H), 6.08 (s, 1H),  6.29 (dd, J = 9.6 Hz, 
5.6 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.55 (t, J = 7.2 
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Hz, 1H), 7.74 (dd, J = 6.8 Hz, 1.6Hz, 2H), 7.98 (d, J = 7.2 Hz, 2H), 8.07 (s, 1H), 
8.66 (s, 1H), 9.31 (s, 1H). 13C NMR (100 MHz, CDCl3): δ 12.0, 17.9, 21.6, 40.8, 
69.9, 70.1, 72.7, 87.1, 89.6, 124.4, 127.8, 127.9, 128.7, 129.8, 132.4, 132.8, 
133.3, 142.7, 145.0, 150.2, 150.6, 151.9, 164.6. HRMS (pos.): 696.3272 [M+H]+ 
(HSMS calc. 696.2887). 
 
Compound 14 
 Compound 14H and 14L shared the same procedure as 
described below: 
Compound 13 (13H or 13L, 1.39 g, 2.0 mmol), and sodium 
iodide (1.50 g, 10.0 mmol) were dissolved in dry acetone (25 mL), then heated 
to reflux for 4 to 6 hours. The solid suspension was removed by celite 
filtration, and the filtrate was concentrated under rotary evaporator. The 
crude product was purified by flash chromatography (DCM:MeOH = 98:2) to 
yield the compound 14 (14H: 1.24 g, 95%; 14L: 1.21 g, 93%) as white solid. 
 
14H: TLC Rf: 0.28 (DCM:MeOH = 97:3). 1H NMR (400 MHz, CDCl3): δ 1.06-
1.11 (m, 21H), 2.28 (dd, J = 12.8 Hz, 5.6 Hz, 1H), 3.04 (m, 1H), 3.17 (t, J = 9.6 
Hz, 1H), 3.27 (m, 1H), 3.97 (m, 1H), 4.64 (s, 1H), 4.74 (d, J = 4.4 Hz, 1H), 6.37 
(dd, J = 5.6 Hz, 9.6 Hz, 1H), 6.56 (d, J = 12.4 Hz, 1H), 7.52 (t, J = 7.2 Hz, 2H), 
7.61 (t, J = 7.2 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 8.07 (s, 1H), 8.75 (s, 1H), 8.97 
(s, 1H).  13C NMR (100 MHz, CDCl3): δ 6.1, 12.0, 18.0, 41.0, 72.7, 75.4, 88.2, 
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89.0, 124.7, 127.9, 129.0, 133.0, 133.4, 142.6, 150.4, 150.5, 151.9, 164.3. 
HRMS (pos.): 652.1815 [M+H]+ (HSMS calc. 652.1811). 
 
14L: TLC Rf: 0.25 (DCM:IPA = 97:3). 1H NMR (400 MHz, CDCl3): δ 1.09-1.14 
(m, 21H), 2.33 (dd, J = 13.2 Hz, 5.2 Hz, 1H), 3.09 (m, 1H), 3.30 (m, 2H), 4.08 
(m, 1H), 4.24 (d, J = 4.4 Hz, 1H), 5.93 (d, J = 2.8 Hz, 1H), 6.36 (m, 1H), 7.48 (t, 
J = 7.6 Hz, 2H), 7.57 (t, J = 7.6 Hz, 1H), 8.02 (d, J = 7.2 Hz, 2H), 8.12 (s, 1H), 
8.74 (s, 1H), 9.57 (s, 1H).  13C NMR (100 MHz, CDCl3): δ 7.1, 12.0, 17.9, 40.7, 
72.7, 75.4, 87.0, 90.8, 124.3, 127.9, 128.6, 132.6, 133.3, 142.7, 150.1, 150.6, 
151.9, 164.8. HRMS (pos.): 652.1826 [M+H]+ (HSMS calc. 652.1811). 
 
Compound 15 
 Compound 15S (15H) and 15R (15L) shared the same 
procedure as described below: 
Compound 14 (14H or 14L, 0.8 g, 1.2 mmol) and zinc powder 
(1.6 g, 24.0 mmol) were dissolved in dry pyridine (40 mL) and sonicated for 
overnight. The zinc powder was removed by filtration and the filtrate was 
concentrated under reduced pressure. The residue and tetrachloro-1,4-
benzoquinone (0.27 g, 1.1 mmol) were dissolved in benzene (60 mL) and 
refluxed for 1 hour. The solvent was then evaporated under vacuum and the 
crude product was purified by flash chromatography (DCM/IPA 97:3) to yield 
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the cyclized product as a pale-yellow foam (15S : 57.0 mg, 9%; 15R : 63.0 mg, 
10%). 
 
15S : TLC Rf: 0.16 (DCM:MeOH = 97:3). 1H NMR (400 MHz, CDCl3): δ 1.05-
1.11 (m, 21H), 2.52 (m, 1H), 2.77 (m, 1H), 2.98 (m, 1H), 3.15 (s, 1H), 3.54 (dd, 
J = 15.6 Hz, 3.2 Hz, 1H), 4.15 (d, J = 12.0 Hz, 1H), 4.47 (d, J = 3.6 Hz, 1H), 
4.95 (d, J = 6.4 Hz, 1H), 6.85 (dd, J = 8.0 Hz, 2.0Hz, 1H), 7.47 (t, J = 7.6 Hz, 
2H), 7.56 (t, J = 7.6 Hz, 1H), 7.97 (d, J = 7.6 Hz, 2H), 8.68 (s, 1H), 8.99 (s, 1H). 
13C NMR (100 MHz, CDCl3): δ 11.9, 17.9, 29.7, 35.0, 44.8, 66.6, 71.7, 82.7, 
92.0, 121.7, 127.9, 128.8, 132.7, 133.5, 148.2, 149.7, 152.1, 152.7, 164.8. 
HRMS (pos.): 524.2835 [M+H]+ (HSMS calc. 524.2693). 
 
15R : TLC Rf: 0.16 (DCM:MeOH = 97:3). 1H NMR (400 MHz, CDCl3): δ 1.06-
1.15 (m, 21H), 2.56 (m, 1H), 2.73 (m, 1H), 2.94 (dd, J = 16 Hz, 2.4 Hz, 1H), 
3.51 (dd, J = 16Hz, 4.0 Hz,1H), 4.07 (s, 1H), 4.57 (d, J = 6.0 Hz, 1H), 4.66 (d, J 
= 2.8 Hz, 1H), 6.81 (dd, J = 8.4 Hz, 2.0Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.50 
(t, J = 7.6 Hz, 1H), 8.12 (d, J = 7.6 Hz, 2H), 8.47 (s, 1H), 9.03 (s, 1H). 13C NMR 
(100 MHz, CDCl3): δ 11.9, 17.9, 29.7, 34.6, 43.8, 66.9, 73.5, 82.2, 93.1, 121.9, 
128.3, 128.6, 132.5, 133.5, 147.6, 151.9, 152.0, 152.3, 165.0.  HRMS (pos.): 
524.2821 [M+H]+ (HSMS calc. 524.2693). 
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Compound 3 
 Compound 3S and 3R shared the same procedure: 
Compound 15 (15S or 15R, 30.0 mg, 55.0 μmol) was dissolved 
in dry THF (3 mL) and added in 1M of TBAF/THF solution (1 
mL). The mixture was stirred under room temperature for 30 minutes, then 
the solvent was removed by rotary evaporator. The residue was treated with 
7N ammonia in methanol (10 mL) under room temperature for overnight. 
The solution was then dried under vacuum and the crude product was 
purified by reverse phase C18 column on high-performance liquid 
chromatography (Water/acetonitrile) to yield the free ring-expanded cyclo-
nucleoside as a white powder (3S : 12.0 mg, 80%; 3R : 13.2 mg, 88%). 
 
3S : TLC Rf: 0.27 (DCM:MeOH = 91:9). 1H NMR (400 MHz, D2O:Pyr-d5 = 7:3): 
δ 2.20 (m, 1H), 2.52 (m, 1H), 2.70 (dd, J = 12.4, 9.6 Hz, 1H), 3.10 (dd, J = 12.8, 
2.4 Hz, 1H), 3.73 (dt, J = 9.2, 3.6 Hz, 1H), 4.34 (d, J = 2.4 Hz, 1H), 4.71 (d, J = 
5.2 Hz, 1H), 6.26 (dd, J = 6.8, 1.6 Hz, 1H), 7.79 (s, 1H). 13C NMR (100 MHz, 
D2O:Pyr-d5 = 7:3): δ 32.4, 41.4, 65.2, 69.5, 81.7, 90.3, 115.6, 146.4, 147.7, 
151.2, 153.6. HRMS (pos.): 264.1098 [M+H]+ (HSMS calc. 264.1097). 
 
3R : TLC Rf: 0.24 (DCM:MeOH = 91:9). 1H NMR (400 MHz, D2O:Pyr-d5 = 
7:3): δ 2.27 (m, 1H), 2.50 (m, 1H), 2.83 (dd, J = 13.6, 1.6 Hz, 1H), 3.12 (m, 1H), 
4.00 (m, 1H), 4.45 (d, J = 5.2 Hz, 1H), 4.47 (d, J = 2.0 Hz, 1H), 6.34 (dd, J = 
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6.4, 2.0 Hz, 1H), 7.73 (s, 1H). 13C NMR (100 MHz, D2O:Pyr-d5 = 7:3): δ 32.2, 
40.7, 65.2, 71.2, 81.7, 91.2, 115.8, 147.9, 149.2, 151.0, 153.4. HRMS (pos.): 
264.1107 [M+H]+ (HSMS calc. 264.1097). 
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3.7. NMR Spectral Data 
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Chapter 4 
Alternate Design – 5’-Hydroxymethyl-8,5’-Cyclo-2’,5’- 
Dideoxy Nucleic Acids 
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4. Alternate Design – 5’-Hydroxymethyl-Cyclo-2’,5’-Dideoxynucleic 
Acids 
 
4.1. Introduction 
In the last two chapters, we successfully synthesized the cyclo-2’-
deoxynucleosides and ring-expanded cyclo-2’-deoxynucleosides (Figure 4.1). 
In chapter 2, we presented the synthesis of the S and R diastereomers for 
both 8,5’-cyclo-2’-deoxyadenosines and 6,5’-cyclo-2’deoxyuridines (Figure 4.1, 
1R, 1S, 2R, and 2S), then incorporated these rigidified nucleosides into a 
DNA sequence to study their thermal behaviour.1 The cyclo-2’-nucleosides 
possessed a second covalent linkage between the sugar and base moieties 
which restricted the base rotation around the glycosidic bond. This linkage 
not only rigidified the structure, but “pulled” the nucleobase away from the 
helical center, which resulted in the destabilization of the double helix 
structure. In nature, 8,5’-cyclo-2’-deoxyadenosines can be formed through 
oxidative damage to DNA. It is known that these cyclo-nucleosides inhibit 
binding of proteins such as the TATA binding protein.2,3 
In chapter 3, we discussed the synthesis of a new generation of 
rigidified nucleosides, the ring-expanded cyclo-nucleosides. When compared 
to the cyclo-nucleosides in chapter 2, we inserted an extra carbon onto the 
bridge between the base and the sugar to expand the cyclized ring on these 
modified nucleosides (Figure 4.1, 3R and 3S). By introducing an extra 
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methylene into the cyclized linkage, we could “push” the base back towards 
its natural position and the linkage should still decrease the entropic penalty 
associated with rotation around the glycosidic bond. The stereochemistry of 
the newly generated chiral center on the C5’ position was characterized by 
2D-NMR experiements. 
 
 
 
 
Figure 4.1. The structures of 8,5’-cyclo-2’-deoxyadenosines (1R, 1S), 6,5’-cyclo-
2’deoxyuridines (2R, 2S), and ring-expanded 8,5’-cyclo-2’-deoxynucleosides 
(3R , 3S). 
 
Here we discuss three different strategies to synthesize another class 
of rigidified nucleosides, 5’-hydroxymethyl-8,5’-cyclo-2’,5’-dideoxyadenosines 
(Figure 4.2.a). The goal of synthesizing these modified nucleosides was to 
generate nucleosides with better thermal stability during duplex formation 
by having better base-paring accessibility and minimized entropic cost. The 
new design has an extra carbon atom (C6’) to elongate the sugar backbone. 
The primary 6’-OH can adopt a variety of conformations, not like the 
rigidified structure in cyclo-nucleosides (1R, 1S, 2R, and 2S) which have 
secondary hydroxyls on the C5’ position fixing their orientation (Figure 4.2.b). 
It gives the structure more flexibility during duplex hybridization, which 
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might result in better accessibility to from hydrogen bonds with their base-
pairing partners than the first generation of cyclo-nucleosides.4 This primary 
6’-OH also allows us to utilize the conventional acid-labile trityl protecting 
group, DMTr. Conventionally available phosphoramidite reagents (chapter 2) 
contain an acid labile DMTr group at the O5’, while for the 8,5’-cyclo-2’-
deoxyadenosines and 6,5’-cyclo-2’deoxyuridines, we needed to utilize EVE 
instead of the bulky DMTrCl to protect the O5’ position due to the steric 
hindrance on the cyclized structure.1 One drawback of this 1-ethylethoxy 
group was its lack of UV activity, therefore the coupling yield could not be 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. a) The structures of 5’-hydroxymethyl-8,5’-cyclo-2’,5’-
dideoxyadenosines. b) 6’-OH rotates around the C5’ – C6’ bond in 4R, and the 
fixed orientation of the 5’-OH on 1R. 
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monitored during DNA synthesis. Another feature of these new rigidified 
nucleosides is that they still possess the secondary linkage to restrict the 
nucleobase rotation around the glycosidic bond, which reduces the entropic 
effect compared to the native nucleosides. 
 
 
4.2. Evaluation of the Synthetic Strategy 
There were several studies on the syntheses and biological 
characterization of the C5’-hydroxymethyl nucleosides in the past few 
decades. In 1960’s, the 5’-hydroxymethyl-5’-deoxyadenosine and the 5’-
hydroxymethyl-2’,5’-dideoxythymidine had already been synthesized.5,6 In 
2005, the 5’-hydroxylmethyl-5’-deoxyadenosine (5’-homoaristeromycin) had 
been made by the Schneller group who also investigated the antiviral activity 
against orthopox viruses.7 However a practical synthetic strategy for 5’-
hydroxymethyl-cyclo-nucleic acids was still needed. Here we discuss three 
different strategies of introducing an extra methylene group onto the C5’ 
position of the 8,5’-cyclo-2’-deoxynucleosides to discover the possibility of 
synthesizing these novel rigidified nucleosides. 
 The first synthetic strategy that we investigated started with one 
important intermediate from the 8,5’-cyclo-2’-deoxyadenosines synthesis, the  
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5’-keto-8,5’-cyclo-2’-deoxyadenosine (compound 5).1 We first wanted to 
generate an epoxide on the C5’ position of compound 5 toward the carbonyl  
group, then followed by reducing the 5’-spiro-epoxide into 5’-hydroxymethyl 
(Sheme 4.1).8,9 It might give two diastereomers after the epoxidation reaction, 
but due to the steric hindrance of the structure the nucleophile could only 
attack the C5’ from the less hindered position to give one diastereomer 
exclusively.8 
 
 
 
 
 
 
 
 
Scheme 4.1. Retrosynthesis of 5’-hydroxymethyl-8,5’-cyclo-2’,5’-dideoxy-
adenosine. The synthesis started with compound 5, an intermediate of the 
8,5’-cyclo-2’-deoxyadenosine synthesis. 
 
 
 
Compound 5 was obtained by a six-step synthesis from deoxyadenosine 
with 19% yield, detail of the procedures were described in chapter 2.1 To 
perform the epoxidation on the carbonyl position, we treated compound 5 
with trimethylsilyldiazomethane in dichloromethane at low temperatures. 
Trimethylsilyldiazomethane is a widely used methylation reagent as a less-
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explosive replacement for diazomethane.10  Unfortunately, we could not 
install the epoxide on the C5’ position (Scheme 4.2) to get to compound 6, 
although this pathway had been established for the cyclo-uridine 
derivatives.11 The reason could be the exo-cyclic amide group on the C6 
position was interfering with the reagent.12 
 
 
 
 
 
 
Scheme 4.2. First synthetic strategy for 5’-hydroxymethyl-8,5’-cyclo-2’,5’-
dideoxyadenosine through epoxidation on the carbonyl group of compound 5. 
 
 
 In the second strategy, we tried to insert the extra carbon and oxygen 
in different steps. First, the extra methylene group was installed onto the C5’ 
of compound 5, then hydroxylated at the C6’ position to obtain the 
hydroxymethyl compound (Scheme 4.3.). The benefit of this route was that 
both diastereomers would be obtained at the end of the synthesis and it also 
started with the same intermediate, compound 5. This strategy has also been 
shown as practical on furanyl scaffolds.13 
 The reaction went through the Wittig olefination to insert the extra 
carbon on C5’ position (Scheme 4.4). The Wittig reagent was prepared from 
the phosphonium salt, methyltriphenylphosphonium bromide, reacting with 
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Scheme 4.3. Retrosynthesis of the second strategy for synthesizing 5’-
hydroxymethyl-8,5’-cyclo-2’,5’-dideoxyadenosine. 
 
 
potassium tert-butoxide (tBuOK) to form the triphenyl phosphonium ylide. 
This was then reacted with the carbonyl group on compound 5 to get 
compound 7. The next step was to oxidize the terminal olefin into the 
hydroxymethyl group by hydroboration-oxidation reaction. Hydroboration-
oxidation is a two-step reaction that converts an alkene group into alcohol. It 
is a syn-addition reaction leading to cis-conformation with the hydroxyl group 
attaching to the less-substituted carbon.14 In the first attempt, we used 9-
borabicyclo[3.3.1]nonane (9-BBN), a more stable borane derivative, to 
possibly give only one dominant diastereomer due to the highly 
stereoselective nature.15 Unfortunately, the 9-BBN hydroboration did not 
work due to the very rigid structure of the cyclo-nucleoside (7). We then tried 
a less hindered, non-stereoselective borane reagent, dimethylsulfide borane 
(BH3-DMS).16  The reaction was unable to give the desired product but 
generated compound 8 and 9 instead (Scheme 4.4). Compound 8 and 9 were 
identified from the doublet -CH3 peak on the H-NMR of the crude product 
and the mass spectra. 
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Scheme 4.4. Second synthetic strategy for synthesizing 5’-hydroxymethyl-8,5’-
cyclo-2’,5’-dideoxyadenosine. 
 
 
 Since the Wittig reaction was shown to be successfully applied to our 
second strategy, in the third synthetic strategy we chose to use another 
Wittig reaction to attach both C6’ and O6’ in one reaction (Scheme 4.5). After 
the installation of the methoxyethylene group, the 5’-hydroxymethyl-cyclo-
nucleosides could be generated by the reduction of the C-C double bond and 
the removal of the methoxy group. Both diastereomers (5’-hydroxymethyl-
8,5’(R)-cyclo-2’,5’-dideoxyadenosine and 5’-hydroxymethyl-8,5’(S)-cyclo-2’,5’-
dideoxyadenosine) could be obtained from this synthetic strategy. 
 (Methoxymethyl)triphenylphosphonium bromide was first reacted with 
tBuOK to generate the Wittig reagent. Then the THF solution of compound 5 
was added into the previous mixture and reacted under elevated temperature 
to produce compound 10 in high yield. The Wittig reaction exclusively gave a 
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single isomer of compound 10, as shown using NMR. After getting the 
methoxyethylene compound (10), there were two different routes to get the 
target 5’-hydroxymethyl-cyclo-nucleosides: a) first, the reduction of the C5’-
C6’ double bond, then deprotection of the 6’-methoxy; b) second, removal of 
the protecting group first, then the reduction.  
 
 
 
 
 
 
Scheme 4.5. Retrosynthesis of the third strategy for synthesizing 5’-
hydroxymethyl-8,5’-cyclo-2’,5’-dideoxyadenosine with a different Wittig 
reaction to insert C6’ and O6’ in one step. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.6. The synthetic scheme of the third strategy for synthesizing 5’-
hydroxymethyl-8,5’-cyclo-2’,5’-dideoxyadenosine. 
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We first tried to reduce the C5’-C6’ double bond with hydrogen 
catalyzed by platinum on charcoal. The reaction was started with 30 psi of 
hydrogen pressure, there was no significant change after reacting overnight 
and monitoring by TLC. Then the hydrogen pressure was increased to 50 psi 
for another period of 12-18 hours generating a new spot which had a slightly 
higher polarity then the starting material. This was the debenzoylated side 
product as identified by the mass spectrum of the crude reaction mixute, but 
the majority was remaining starting material, compound 10. Then we 
performed an alternate route b to remove the methoxy group first. The 
methoxy deprotection was carried out with boron tribromide (BBr3), a strong 
Lewis acid, in hexane.17 The resulting compound 10 was first dissolved in 
DCM, then the solution was brought to -78 oC in a dry ice/acetone bath. BBr3 
was then added as a solution in hexane into the cold DCM solution. After 3 
hours TLC indicated completion of the reaction. The resulting compound 12 
was not purified since the aldehyde compound was found to be unstable 
under silica gel column conditions. After the workup, the crude mixture was 
treated with sodium borohydride in ethanol to reduce the aldehyde group 
generating both R and S diastereomers. The combined yield for 13R and 13S  
was not optimal, and there were some debenzoylated side products 
(compound 14) generated which could be identified by mass spectrometry. 
These two diastereomers could be barely separated by TLC, and since they 
were unable to be purified by column chromatography, we utilized 
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preparative TLC to separate them instead. According to the relation between 
the structure and the polarity, we assumed that the compound developing 
lower on the TLC, which had higher polarity, should be the S – diastereomer 
due to the more accessible hydroxyl group to the silica gel on the 6’ position; 
the higher spot on the TLC should be the R diastereomer (Figure 4.3). 
 
 
 
 
 
 
 
 
Figure 4.3. TLC of the compound 13R and 13S. The plate was developed in 
5% methanol in DCM, two times in order to observe the polarity difference of 
these two diastereomers. 
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4.3. Conclusions 
 In this chapter we presented the possible synthetic strategies for 
synthesizing the novel rigidified nucleosides: the 5’-hydroxymethyl-8,5’-cyclo-
2’,5’-dideoxyadenosines. We discussed and performed three different 
strategies and 4 synthetic routes to investigate the possibility of synthesizing 
both diastereomers. The first strategy showed that the epoxidation with 
diazomethane based reagent on the cyclo-deoxyadenosine was not feasible. In 
the second strategy, we learned the hydroboration-oxidation could not 
happen on the cyclo-deoxyadenosine derivative, but we learned that the 
Wittig reaction was a practical way to install varied functional groups onto 
the C5’ position of the cyclo-nucleoside. Utilizing the versatile intermediate, 
compound 5, we established a workable pathway to synthesize the 5’-
hydroxymethyl-8,5’-cyclo-2’,5’-dideoxyadenosine derivatives of both 
diastereomers. It could be a valuable reference for people who are interested 
in investigating the total synthesis and the biophysical properties of these 
rigidified nucleosides. 
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4.4. Experimental 
 
Reagents were purchased from Sigma-Aldrich, Acros, Oakwood, MP 
Biomedical, Chem-Impex International, Fisher. Flash column were 
performed using Dynamic Adsorbents silica gel (60 Å, particle size 32-63 m), 
Preparative TLC was from Analtech (1000 microns with F-254 Indicator), 
TLC monitoring with TLC Silica Gel with F-254 Indicator (Dynamic 
Adsorbents). TLCs were visualized by 260nm UV light and stained by 10% 
sulfuric acid. Dry tetrahydrofuran (THF) and dichloromethane (DCM) were 
obtained by passing commercially available pre-dried, oxygen-free 
formulations through activated alumina columns. Dry ethanol was purchased 
from Sigma-Aldrich and used directly. NMR spectra were taken by Varian 
VNMRS400, VNMRS500, or INOVA 500 instruments and calibrated using 
residual undeuterated solvent (CDCl3: δ H = 7.24 ppm, δ C = 77.00 ppm). 
Abbreviations of multiplicities were designated as follow: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra 
(HRMS) were recorded on a Waters LCT or JEOL AccuTOF mass 
spectrometer using ESI (electrospray ionization) or DART (direct analysis in 
real time). 
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Compound 7 
 Methyltriphenylphosphonium bromide (0.35 g, 0.98 
mmol) was dissolved in dry THF (3.5 mL) under room 
temperature, and tBuOK (0.10 g, 0.86 mmol) was slowly adde 
into the solution. The mixture was allowed to react for an hour then a THF 
solution of Compound 5 (0.125 g, 0.25 mmol in 1 mL THF) was added into the 
reaction mixture. After stirring for overnight under ambient temperature, the 
reaction was quenched with concentrated NH4Cl(aq) (2mL). DCM (10 mL) was 
added and the solution was extracted extracted with water three times and 
once with brine. The organic layer was dried over sodium sulfate and 
concentrated under vacuum. The crude product was purified by flash 
chromatography (DCM:MeOH = 97.5:2.5) to yield compound 7 as a white 
solid (0.89 g, 72%). TLC Rf: 0.40 (DCM:MeOH = 97.5:2.5). 1H NMR (500 MHz, 
CDCl3): δ 1.03-1.12 (m, 21H), 2.43 (d, J = 12.5 Hz, 1H), 2.68 (m, 1H), 4.57 (d, J 
= 4.0 Hz, 1H), 5.08 (s, 1H), 5.54 (s, 1H), 6.44 (s, 1H), 6.66 (d, J = 5.5 Hz, 1H), 
7.52 (t, J = 7.0 Hz, 2H), 7.59 (t, J = 7.0 Hz, 1H), 8.00 (d, J = 6.5 Hz, 2H), 8.74 
(s, 1H), 9.03 (s, 1H). HRMS (pos.): 506.2591 [M+H]+ (HSMS calc. 506.2587). 
 
 
Compound 10 
 Methoxymethyltriphenylphosphonium bromide (1.51 
g, 4.4 mmol) was dissolved in THF (16 mL) under room 
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temperature, and tBuOK (0.43 g, 3.85 mmol) was slowly adde into the 
solution. The mixture was allowed to react for an hour then a THF solution of 
Compound 5 (0.56 g, 1.10 mmol in 4 mL THF) was added into the reaction 
mixture. After stirring for overnight under ambient temperature, the reaction 
was quenched with concentrated NH4Cl(aq) (10mL). DCM (25 mL) was added 
and the solution was extracted extracted with water three times and once 
with brine. The organic layer was dried over sodium sulfate and concentrated 
under vacuum. The crude product was purified by flash chromatography 
(DCM:MeOH = 97.5:2.5) to yield compound 10 as a white solid (0.58 g, 95%). 
TLC Rf: 0.25 (DCM:MeOH = 97:3). 1H NMR (500 MHz, CDCl3): δ 1.06-1.13 
(m, 21H), 2.43 (m, 1H), 2.63 (m, 1H), 3.91 (s, 3H), 4.52 (dd, J = 14.0, 6.5 Hz, 
1H), 5.40 (s, 1H), 6.61 (d, J = 5.5 Hz, 1H), 7.46 (td, J = 7.5, 3.0 Hz, 1H), 7.51 
(m, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.66 (m, 1H), 8.00 (d, J = 7.5 Hz, 2H), 8.63 (s, 
1H), 8.98 (s, 1H). HRMS (pos.): 536.2702 [M+H]+ (HSMS calc. 536.2693). 
 
 
Compound 12 
 Compound 10 (0.1 g, 0.2 mmol) was dissolved in dry 
DCM (52 mL) and cooled to -78 oC in dry ice/acetone bath.  
Boron tribromide/hexan solution (1 M, 2.0 mL) was added 
and the reaction was kept stirring at -78 oC. After reacting for 3 hours the 
reaction was quenched with diethyl ether (5 mL) on dry ice/acetone bath for 
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10 minutes. The mixture was diluted with DCM (50 mL) and extracted with 
concentrated NaHCO3(aq) once, water three times and once with brine soltion. 
The organic layer was dried over sodium sulfate and concentrated under 
vacuum. The crude product was staying on high vacuum for overnight then 
directly went onto next step. 
 
Compound 13S  and 13R 
 The crude compound 12 (started from 0.5 mmol of compound 10) and 
sodium borohydride (19 mg, 0.5 mmol) were dissolved in dry ethanol (100 
mL). The reaction mixture stirred under room temperature for one and half 
hours then quenched with water. The mixture was diluted with DCM and 
extracted with water three times and once with brine.  The organic layer was 
dried over sodium sulfate and concentrated under vacuum.  The crude 
product was purified by preparative TLC (DCM:MeOH = 95:5) to yield 
compound 13S and 13R as a white powder (13S : 15 mg, 13R : 10 mg, total 
yield: 10% ).  TLC Rf: 13S : 0.26,  13R : 0.31 (DCM:MeOH = 95:5, developed 
twice). 
 
 13S  
 1H NMR (400 MHz, CDCl3): δ 1.06-1.10 (m, 21H), 1.94 
(dd, J = 16.0, 3.5 Hz, 1H), 2.12 (m, 2H), 2.47 (m, 1H), 2.57 (d, 
J = 11.5 Hz, 1H), 3.86 (d, J = 9.5 Hz, 1H), 4.33 (d, J = 10.0 
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Hz, 1H), 4.67 (d, J = 9.5 Hz, 1H), 7.57 (t, J = 9.5 Hz, 2H), 7.67 (t, J = 9.5 Hz, 
1H), 7.98 (td, J = 9.5, 1.0 Hz, 2H), 8.71 (s, 1H), 8.89 (s, 1H). 13C NMR 
(100MHz, CDCl3): δ 12.8, 18.0, 29.7, 42.2, 47.6, 50.4, 70.2, 74.1, 108.0, 113.4, 
127.7, 129.3, 133.6, 146.3, 152.2. HRMS (pos.): 524.2690 [M+H]+ (HSMS calc. 
524.2693). 
 
13R  
 δ 1.06-1.09 (m, 21H), 1.94 (dt, J = 16.0, 5.0 Hz, 1H), 
2.13-2.17 (m, 2H), 2.39 (dd, J = 16.0, 13.0 Hz, 1H), 2.50 (dd, J 
= 12.0, 4.5 Hz, 1H), 4.02 (dd, J = 9.0, 2.0 Hz, 1H), 4.70-4.75 
(m, 2H), 7.57 (td, J = 9.0, 2.0 Hz, 2H), 7.67 (tt, J = 9.0, 1.5 Hz, 1H), 7.99 (dt, J 
= 9.0, 1.5 Hz, 2H), 8.72 (s, 1H), 8.90 (s, 1H). 13C NMR (100MHz, CDCl3): δ 
12.8, 18.0, 29.7, 44.1, 44.8, 50.6, 68.9, 73.0, 108.0, 113.4, 127.7, 129.3, 132.1, 
133.6, 142.3, 152.2, 157.0, 162.6, 166.5. HRMS (pos.): 524.2669 [M+H]+ 
(HSMS calc. 524.2693). 
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4.6. NMR Spectral Data 
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